CN115417856A - 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 - Google Patents
一类取代杂芳酞嗪衍生物的药学用途及其制备方法 Download PDFInfo
- Publication number
- CN115417856A CN115417856A CN202211210361.XA CN202211210361A CN115417856A CN 115417856 A CN115417856 A CN 115417856A CN 202211210361 A CN202211210361 A CN 202211210361A CN 115417856 A CN115417856 A CN 115417856A
- Authority
- CN
- China
- Prior art keywords
- alkyl radical
- compound
- radical
- cycloalkyl
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 claims abstract description 19
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 claims abstract 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 309
- 150000001875 compounds Chemical class 0.000 claims description 281
- -1 Alkoxy radical Chemical class 0.000 claims description 263
- 238000006243 chemical reaction Methods 0.000 claims description 243
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 164
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 116
- 238000000034 method Methods 0.000 claims description 71
- 238000004440 column chromatography Methods 0.000 claims description 70
- 229910052736 halogen Inorganic materials 0.000 claims description 70
- 150000002367 halogens Chemical class 0.000 claims description 60
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 58
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 58
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 claims description 57
- 239000012046 mixed solvent Substances 0.000 claims description 57
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 57
- 125000000217 alkyl group Chemical group 0.000 claims description 51
- 238000006467 substitution reaction Methods 0.000 claims description 51
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 50
- 125000004429 atom Chemical group 0.000 claims description 50
- 229910052757 nitrogen Inorganic materials 0.000 claims description 50
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 44
- 229910052739 hydrogen Inorganic materials 0.000 claims description 41
- 239000001257 hydrogen Substances 0.000 claims description 41
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 41
- 125000001072 heteroaryl group Chemical group 0.000 claims description 39
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 37
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 37
- 150000002431 hydrogen Chemical class 0.000 claims description 36
- 150000003839 salts Chemical class 0.000 claims description 34
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 33
- 229910052717 sulfur Inorganic materials 0.000 claims description 32
- 229910052760 oxygen Inorganic materials 0.000 claims description 31
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 claims description 31
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 125000001505 phosphinoxide group Chemical group 0.000 claims description 26
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 24
- 125000003545 alkoxy group Chemical group 0.000 claims description 23
- 125000002947 alkylene group Chemical group 0.000 claims description 23
- 150000003004 phosphinoxides Chemical class 0.000 claims description 23
- 125000003386 piperidinyl group Chemical group 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 21
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 20
- 229910052805 deuterium Inorganic materials 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 239000005457 ice water Substances 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 125000001153 fluoro group Chemical group F* 0.000 claims description 17
- 125000002252 acyl group Chemical group 0.000 claims description 16
- 125000004076 pyridyl group Chemical group 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 14
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 150000001412 amines Chemical class 0.000 claims description 11
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 238000000926 separation method Methods 0.000 claims description 9
- 235000019000 fluorine Nutrition 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 8
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 8
- 239000012295 chemical reaction liquid Substances 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- SFHYNDMGZXWXBU-LIMNOBDPSA-N 6-amino-2-[[(e)-(3-formylphenyl)methylideneamino]carbamoylamino]-1,3-dioxobenzo[de]isoquinoline-5,8-disulfonic acid Chemical compound O=C1C(C2=3)=CC(S(O)(=O)=O)=CC=3C(N)=C(S(O)(=O)=O)C=C2C(=O)N1NC(=O)N\N=C\C1=CC=CC(C=O)=C1 SFHYNDMGZXWXBU-LIMNOBDPSA-N 0.000 claims description 6
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 229910052731 fluorine Inorganic materials 0.000 claims description 6
- 239000011737 fluorine Substances 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- WQAWEUZTDVWTDB-UHFFFAOYSA-N dimethyl(oxo)phosphanium Chemical compound C[P+](C)=O WQAWEUZTDVWTDB-UHFFFAOYSA-N 0.000 claims description 5
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 4
- 239000012043 crude product Substances 0.000 claims description 4
- MDDUHVRJJAFRAU-YZNNVMRBSA-N tert-butyl-[(1r,3s,5z)-3-[tert-butyl(dimethyl)silyl]oxy-5-(2-diphenylphosphorylethylidene)-4-methylidenecyclohexyl]oxy-dimethylsilane Chemical compound C1[C@@H](O[Si](C)(C)C(C)(C)C)C[C@H](O[Si](C)(C)C(C)(C)C)C(=C)\C1=C/CP(=O)(C=1C=CC=CC=1)C1=CC=CC=C1 MDDUHVRJJAFRAU-YZNNVMRBSA-N 0.000 claims description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 3
- 239000004327 boric acid Substances 0.000 claims description 3
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- GOJNABIZVJCYFL-UHFFFAOYSA-N dimethylphosphinic acid Chemical compound CP(C)(O)=O GOJNABIZVJCYFL-UHFFFAOYSA-N 0.000 claims description 2
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 239000003112 inhibitor Substances 0.000 abstract description 8
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 172
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 123
- 239000000203 mixture Substances 0.000 description 112
- 239000000243 solution Substances 0.000 description 99
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 96
- 239000012074 organic phase Substances 0.000 description 96
- 239000002904 solvent Substances 0.000 description 96
- 239000000706 filtrate Substances 0.000 description 94
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 94
- 230000002829 reductive effect Effects 0.000 description 89
- 238000004809 thin layer chromatography Methods 0.000 description 77
- 239000000460 chlorine Substances 0.000 description 57
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 48
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- 239000011541 reaction mixture Substances 0.000 description 47
- 239000007858 starting material Substances 0.000 description 43
- GYGNUMOLFBSVCL-UHFFFAOYSA-N [2-hydroxy-4-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(C(F)(F)F)C=C1O GYGNUMOLFBSVCL-UHFFFAOYSA-N 0.000 description 40
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 38
- 230000015572 biosynthetic process Effects 0.000 description 36
- 238000003786 synthesis reaction Methods 0.000 description 36
- 239000004698 Polyethylene Substances 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 23
- 238000001035 drying Methods 0.000 description 21
- QZSACHHNFDNCNB-ZCFIWIBFSA-N (3r)-1-methylpiperidin-3-amine Chemical compound CN1CCC[C@@H](N)C1 QZSACHHNFDNCNB-ZCFIWIBFSA-N 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 238000001914 filtration Methods 0.000 description 18
- 238000010898 silica gel chromatography Methods 0.000 description 18
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 15
- 239000012065 filter cake Substances 0.000 description 15
- 230000004054 inflammatory process Effects 0.000 description 15
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 102000012064 NLR Proteins Human genes 0.000 description 11
- 108091005686 NOD-like receptors Proteins 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- 238000009987 spinning Methods 0.000 description 10
- 239000010779 crude oil Substances 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 125000004486 1-methylpiperidin-3-yl group Chemical group CN1CC(CCC1)* 0.000 description 7
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 125000001424 substituent group Chemical group 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- 108091008099 NLRP3 inflammasome Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- DANUORFCFTYTSZ-UHFFFAOYSA-N epinigericin Natural products O1C2(C(CC(C)(O2)C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)C)C(C)C(OC)CC1CC1CCC(C)C(C(C)C(O)=O)O1 DANUORFCFTYTSZ-UHFFFAOYSA-N 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- DANUORFCFTYTSZ-BIBFWWMMSA-N nigericin Chemical compound C([C@@H]1C[C@H]([C@H]([C@]2([C@@H](C[C@](C)(O2)C2O[C@@](C)(CC2)C2[C@H](CC(O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C)O1)C)OC)[C@H]1CC[C@H](C)C([C@@H](C)C(O)=O)O1 DANUORFCFTYTSZ-BIBFWWMMSA-N 0.000 description 5
- 108010089193 pattern recognition receptors Proteins 0.000 description 5
- 102000007863 pattern recognition receptors Human genes 0.000 description 5
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 5
- UDJFFSGCRRMVFH-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine Chemical compound N1=CN=CC2=CC=CN=C21 UDJFFSGCRRMVFH-UHFFFAOYSA-N 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 108090000426 Caspase-1 Proteins 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical group [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 4
- 238000005086 pumping Methods 0.000 description 4
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000001291 vacuum drying Methods 0.000 description 4
- 102100035904 Caspase-1 Human genes 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- ALOCUZOKRULSAA-UHFFFAOYSA-N 1-methylpiperidin-4-amine Chemical compound CN1CCC(N)CC1 ALOCUZOKRULSAA-UHFFFAOYSA-N 0.000 description 2
- YVCOPUPWDKEPBL-CQSZACIVSA-N 2-[4-[[(3R)-1-methylpiperidin-3-yl]amino]-5,6,7,8-tetrahydrophthalazin-1-yl]-5-(trifluoromethyl)phenol Chemical compound CN(CCC1)C[C@@H]1NC1=C(CCCC2)C2=C(C(C=CC(C(F)(F)F)=C2)=C2O)N=N1 YVCOPUPWDKEPBL-CQSZACIVSA-N 0.000 description 2
- MFEIKQPHQINPRI-UHFFFAOYSA-N 3-Ethylpyridine Chemical compound CCC1=CC=CN=C1 MFEIKQPHQINPRI-UHFFFAOYSA-N 0.000 description 2
- HMMBJOWWRLZEMI-UHFFFAOYSA-N 4,5,6,7-tetrahydro-2-benzofuran-1,3-dione Chemical compound C1CCCC2=C1C(=O)OC2=O HMMBJOWWRLZEMI-UHFFFAOYSA-N 0.000 description 2
- VNLYHYHJIXGBFX-UHFFFAOYSA-N 4-(trifluoromethyl)phthalic acid Chemical compound OC(=O)C1=CC=C(C(F)(F)F)C=C1C(O)=O VNLYHYHJIXGBFX-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- XVMKZAAFVWXIII-UHFFFAOYSA-N 5-fluoro-2-benzofuran-1,3-dione Chemical compound FC1=CC=C2C(=O)OC(=O)C2=C1 XVMKZAAFVWXIII-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical group [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102000003930 C-Type Lectins Human genes 0.000 description 2
- 108090000342 C-Type Lectins Proteins 0.000 description 2
- 102000002164 CARD domains Human genes 0.000 description 2
- 108050009503 CARD domains Proteins 0.000 description 2
- VUJZUCWROQQCEX-OAHLLOKOSA-N CC(C=C1)=CC(O)=C1C(C1=CC=CC=C11)=NN=C1N[C@H]1CN(C)CCC1 Chemical compound CC(C=C1)=CC(O)=C1C(C1=CC=CC=C11)=NN=C1N[C@H]1CN(C)CCC1 VUJZUCWROQQCEX-OAHLLOKOSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 206010018634 Gouty Arthritis Diseases 0.000 description 2
- 108010034143 Inflammasomes Proteins 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 description 2
- DBYHPSHDFIWHME-UHFFFAOYSA-N OC(CCC1)CC1NC(C1=CC=CC=C11)=NN=C1C(C=CC(C(F)(F)F)=C1)=C1O Chemical compound OC(CCC1)CC1NC(C1=CC=CC=C11)=NN=C1C(C=CC(C(F)(F)F)=C1)=C1O DBYHPSHDFIWHME-UHFFFAOYSA-N 0.000 description 2
- 208000027089 Parkinsonian disease Diseases 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 102000005583 Pyrin Human genes 0.000 description 2
- 108010059278 Pyrin Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 206010069363 Traumatic lung injury Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 229940126209 compound 43b Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- CUIWFAXEALIQJS-UHFFFAOYSA-N dimethyl 1h-imidazole-4,5-dicarboxylate Chemical compound COC(=O)C=1N=CNC=1C(=O)OC CUIWFAXEALIQJS-UHFFFAOYSA-N 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 231100000515 lung injury Toxicity 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000002644 phorbol ester Substances 0.000 description 2
- WTYSCLHDMXBMKM-UHFFFAOYSA-N phthalazin-1-amine Chemical compound C1=CC=C2C(N)=NN=CC2=C1 WTYSCLHDMXBMKM-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- GKTQKQTXHNUFSP-UHFFFAOYSA-N thieno[3,4-c]pyrrole-4,6-dione Chemical compound S1C=C2C(=O)NC(=O)C2=C1 GKTQKQTXHNUFSP-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- HBENZIXOGRCSQN-VQWWACLZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylpentan-2-yl]-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol Chemical compound N1([C@@H]2CC=3C4=C(C(=CC=3)O)O[C@H]3[C@@]5(OC)CC[C@@]2([C@@]43CC1)C[C@@H]5[C@](C)(O)C(C)(C)CC)CC1CC1 HBENZIXOGRCSQN-VQWWACLZSA-N 0.000 description 1
- QGCLEUGNYRXBMZ-ZCFIWIBFSA-N (1r)-1-(4-fluorophenyl)ethanamine Chemical compound C[C@@H](N)C1=CC=C(F)C=C1 QGCLEUGNYRXBMZ-ZCFIWIBFSA-N 0.000 description 1
- PDNHLCRMUIGNBV-ZCFIWIBFSA-N (1r)-1-pyridin-2-ylethanamine Chemical compound C[C@@H](N)C1=CC=CC=N1 PDNHLCRMUIGNBV-ZCFIWIBFSA-N 0.000 description 1
- QGCLEUGNYRXBMZ-LURJTMIESA-N (1s)-1-(4-fluorophenyl)ethanamine Chemical compound C[C@H](N)C1=CC=C(F)C=C1 QGCLEUGNYRXBMZ-LURJTMIESA-N 0.000 description 1
- PDNHLCRMUIGNBV-LURJTMIESA-N (1s)-1-pyridin-2-ylethanamine Chemical compound C[C@H](N)C1=CC=CC=N1 PDNHLCRMUIGNBV-LURJTMIESA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- JHCQENHEMNQVSO-UHFFFAOYSA-N (2-hydroxy-4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C(O)=C1 JHCQENHEMNQVSO-UHFFFAOYSA-N 0.000 description 1
- OJSKCZZLOSEKPH-UHFFFAOYSA-N (2-hydroxy-5-methylphenyl)boronic acid Chemical compound CC1=CC=C(O)C(B(O)O)=C1 OJSKCZZLOSEKPH-UHFFFAOYSA-N 0.000 description 1
- YDMRDHQUQIVWBE-UHFFFAOYSA-N (2-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1O YDMRDHQUQIVWBE-UHFFFAOYSA-N 0.000 description 1
- WVPNPAOHYCCTFY-SSDOTTSWSA-N (2r)-1-ethyl-n-methylpyrrolidin-2-amine Chemical compound CCN1CCC[C@@H]1NC WVPNPAOHYCCTFY-SSDOTTSWSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- PHDIJLFSKNMCMI-ITGJKDDRSA-N (3R,4S,5R,6R)-6-(hydroxymethyl)-4-(8-quinolin-6-yloxyoctoxy)oxane-2,3,5-triol Chemical compound OC[C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)OCCCCCCCCOC=1C=C2C=CC=NC2=CC=1)O PHDIJLFSKNMCMI-ITGJKDDRSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- GOLVGZOPWLLUSF-ZCFIWIBFSA-N (3r)-1-ethylpyrrolidin-3-amine Chemical compound CCN1CC[C@@H](N)C1 GOLVGZOPWLLUSF-ZCFIWIBFSA-N 0.000 description 1
- UNHOPMIDKWXFMF-RXMQYKEDSA-N (3r)-1-methylpyrrolidin-3-amine Chemical compound CN1CC[C@@H](N)C1 UNHOPMIDKWXFMF-RXMQYKEDSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- KOFNQIAWWVBBJZ-UHFFFAOYSA-N (4-fluoro-2-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C=C1O KOFNQIAWWVBBJZ-UHFFFAOYSA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- TWDQSJDFXUMAOI-UHFFFAOYSA-N (5-fluoro-2-hydroxyphenyl)boronic acid Chemical compound OB(O)C1=CC(F)=CC=C1O TWDQSJDFXUMAOI-UHFFFAOYSA-N 0.000 description 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- UQFCPYWBBOXKCP-UHFFFAOYSA-N 1,4-dichloro-6-(trifluoromethyl)phthalazine Chemical compound ClC1=NN=C(Cl)C2=CC(C(F)(F)F)=CC=C21 UQFCPYWBBOXKCP-UHFFFAOYSA-N 0.000 description 1
- JDYKLDHGCUOCSB-UHFFFAOYSA-N 1,4-dichloro-6-fluorophthalazine Chemical compound ClC1=NN=C(Cl)C2=CC(F)=CC=C21 JDYKLDHGCUOCSB-UHFFFAOYSA-N 0.000 description 1
- GOOJANMHEJCGHG-UHFFFAOYSA-N 1,4-dichloro-6-methylphthalazine Chemical compound ClC1=NN=C(Cl)C2=CC(C)=CC=C21 GOOJANMHEJCGHG-UHFFFAOYSA-N 0.000 description 1
- ODCNAEMHGMYADO-UHFFFAOYSA-N 1,4-dichlorophthalazine Chemical compound C1=CC=C2C(Cl)=NN=C(Cl)C2=C1 ODCNAEMHGMYADO-UHFFFAOYSA-N 0.000 description 1
- LMVNXZZDBBSCSG-UHFFFAOYSA-N 1,4-dichloropyrido[3,4-d]pyridazine Chemical compound N1=CC=C2C(Cl)=NN=C(Cl)C2=C1 LMVNXZZDBBSCSG-UHFFFAOYSA-N 0.000 description 1
- ZKOKXNFZOYVVCH-UHFFFAOYSA-N 1,4-dichlorothieno[3,4-d]pyridazine Chemical compound ClC1=NN=C(Cl)C2=CSC=C12 ZKOKXNFZOYVVCH-UHFFFAOYSA-N 0.000 description 1
- MHSLDASSAFCCDO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylpyrazol-3-yl)-3-(4-pyridin-4-yloxyphenyl)urea Chemical compound CN1N=C(C(C)(C)C)C=C1NC(=O)NC(C=C1)=CC=C1OC1=CC=NC=C1 MHSLDASSAFCCDO-UHFFFAOYSA-N 0.000 description 1
- VXNZUUAINFGPBY-UHFFFAOYSA-N 1-Butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- LXQMHOKEXZETKB-UHFFFAOYSA-N 1-amino-2-methylpropan-2-ol Chemical compound CC(C)(O)CN LXQMHOKEXZETKB-UHFFFAOYSA-N 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- XRALMQPXNWQWLB-UHFFFAOYSA-N 1-n,1-dimethylcyclohexane-1,4-diamine Chemical compound CNC1(C)CCC(N)CC1 XRALMQPXNWQWLB-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZUUNZDIGHGJBAR-UHFFFAOYSA-N 1h-imidazole-2,5-dicarboxylic acid Chemical compound OC(=O)C1=CNC(C(O)=O)=N1 ZUUNZDIGHGJBAR-UHFFFAOYSA-N 0.000 description 1
- IQOSUJMDLDGCKD-UHFFFAOYSA-N 2,3,5,6,7,8-hexahydrophthalazine-1,4-dione Chemical compound C1CCCC2=C1C(=O)NNC2=O IQOSUJMDLDGCKD-UHFFFAOYSA-N 0.000 description 1
- KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical compound C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- VGYGUKCLUFVVQO-VPENINKCSA-N 2-deoxyribose 5-triphosphate Chemical compound O[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 VGYGUKCLUFVVQO-VPENINKCSA-N 0.000 description 1
- 125000003858 2-ethylbutoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])O*)C([H])([H])C([H])([H])[H] 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- WVHJBVPYIIBODU-UHFFFAOYSA-N 2-methyl-3h-furan-2-carbaldehyde Chemical compound O=CC1(C)CC=CO1 WVHJBVPYIIBODU-UHFFFAOYSA-N 0.000 description 1
- RSAIIBFKUJGUQI-UHFFFAOYSA-N 2-methylpyridine Chemical compound [CH2]C1=CC=CC=N1 RSAIIBFKUJGUQI-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- NIQIPYGXPZUDDP-UHFFFAOYSA-N 3-aminocyclohexan-1-ol Chemical compound NC1CCCC(O)C1 NIQIPYGXPZUDDP-UHFFFAOYSA-N 0.000 description 1
- RXKXGWDOSOWALX-UHFFFAOYSA-N 4,7-dichloro-3-methylimidazo[4,5-d]pyridazine Chemical compound N1=NC(Cl)=C2N(C)C=NC2=C1Cl RXKXGWDOSOWALX-UHFFFAOYSA-N 0.000 description 1
- WYFCZWSWFGJODV-MIANJLSGSA-N 4-[[(1s)-2-[(e)-3-[3-chloro-2-fluoro-6-(tetrazol-1-yl)phenyl]prop-2-enoyl]-5-(4-methyl-2-oxopiperazin-1-yl)-3,4-dihydro-1h-isoquinoline-1-carbonyl]amino]benzoic acid Chemical compound O=C1CN(C)CCN1C1=CC=CC2=C1CCN(C(=O)\C=C\C=1C(=CC=C(Cl)C=1F)N1N=NN=C1)[C@@H]2C(=O)NC1=CC=C(C(O)=O)C=C1 WYFCZWSWFGJODV-MIANJLSGSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- QNGKPMNRSDSBMD-UHFFFAOYSA-N 5,8-dichloropyrido[2,3-d]pyridazine Chemical compound C1=CC=C2C(Cl)=NN=C(Cl)C2=N1 QNGKPMNRSDSBMD-UHFFFAOYSA-N 0.000 description 1
- MRUUOENIWOPHLR-UHFFFAOYSA-N 6-bromo-1,4-dichlorophthalazine Chemical compound BrC1=CC=C2C(Cl)=NN=C(Cl)C2=C1 MRUUOENIWOPHLR-UHFFFAOYSA-N 0.000 description 1
- BYGQXVMMKIJEDD-UHFFFAOYSA-N 6-fluoro-2,3-dihydrophthalazine-1,4-dione Chemical compound O=C1NNC(=O)C=2C1=CC(F)=CC=2 BYGQXVMMKIJEDD-UHFFFAOYSA-N 0.000 description 1
- YGNIHUPLYZIWOL-UHFFFAOYSA-N 6-methyl-2,3-dihydrophthalazine-1,4-dione Chemical compound O=C1NNC(=O)C=2C1=CC(C)=CC=2 YGNIHUPLYZIWOL-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100021676 Baculoviral IAP repeat-containing protein 1 Human genes 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- GNGZZWTXFNFCMU-OCAPTIKFSA-N CN(C)[C@@H]1CC[C@H](N)CC1 Chemical compound CN(C)[C@@H]1CC[C@H](N)CC1 GNGZZWTXFNFCMU-OCAPTIKFSA-N 0.000 description 1
- GNGZZWTXFNFCMU-ZKCHVHJHSA-N CN(C)[C@H]1CC[C@H](N)CC1 Chemical compound CN(C)[C@H]1CC[C@H](N)CC1 GNGZZWTXFNFCMU-ZKCHVHJHSA-N 0.000 description 1
- PSLBRVZULPGWSH-SNVBAGLBSA-N CN(CCC1)C[C@@H]1NC(C1=C2C=CC=C1)=NN=C2Cl Chemical compound CN(CCC1)C[C@@H]1NC(C1=C2C=CC=C1)=NN=C2Cl PSLBRVZULPGWSH-SNVBAGLBSA-N 0.000 description 1
- RSCVOSOHZCLZCA-GFCCVEGCSA-N CN(CCC1)C[C@@H]1NC(C1=CSC=C11)=NN=C1C(C=CC(C(F)(F)F)=C1)=C1O Chemical compound CN(CCC1)C[C@@H]1NC(C1=CSC=C11)=NN=C1C(C=CC(C(F)(F)F)=C1)=C1O RSCVOSOHZCLZCA-GFCCVEGCSA-N 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- QBOTXZZHDVPGQX-SECBINFHSA-N ClC(C1=CC=CC=C11)=NN=C1N[C@H]1CNCCC1 Chemical compound ClC(C1=CC=CC=C11)=NN=C1N[C@H]1CNCCC1 QBOTXZZHDVPGQX-SECBINFHSA-N 0.000 description 1
- ISZAIJXFELJREM-UHFFFAOYSA-N ClC1=C2C(=C(N=N1)Cl)N(N=C2)C Chemical compound ClC1=C2C(=C(N=N1)Cl)N(N=C2)C ISZAIJXFELJREM-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229940127007 Compound 39 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010069941 DNA receptor Proteins 0.000 description 1
- 102100034289 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Human genes 0.000 description 1
- 101710103779 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Proteins 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101000983747 Homo sapiens MHC class II transactivator Proteins 0.000 description 1
- 101001109463 Homo sapiens NACHT, LRR and PYD domains-containing protein 1 Proteins 0.000 description 1
- 101000962345 Homo sapiens NACHT, LRR and PYD domains-containing protein 12 Proteins 0.000 description 1
- 101001128138 Homo sapiens NACHT, LRR and PYD domains-containing protein 2 Proteins 0.000 description 1
- 101001109455 Homo sapiens NACHT, LRR and PYD domains-containing protein 6 Proteins 0.000 description 1
- 101001128132 Homo sapiens NACHT, LRR and PYD domains-containing protein 7 Proteins 0.000 description 1
- 101000979572 Homo sapiens NLR family CARD domain-containing protein 4 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 1
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 102100026371 MHC class II transactivator Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- 102100022698 NACHT, LRR and PYD domains-containing protein 1 Human genes 0.000 description 1
- 102100039240 NACHT, LRR and PYD domains-containing protein 12 Human genes 0.000 description 1
- 102100031897 NACHT, LRR and PYD domains-containing protein 2 Human genes 0.000 description 1
- 102100022696 NACHT, LRR and PYD domains-containing protein 6 Human genes 0.000 description 1
- 102100031902 NACHT, LRR and PYD domains-containing protein 7 Human genes 0.000 description 1
- 102100023435 NLR family CARD domain-containing protein 4 Human genes 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010006696 Neuronal Apoptosis-Inhibitory Protein Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HYSOPXHRAHXSFM-QMMMGPOBSA-N [(1r)-1-methylcyclohexa-2,4-dien-1-yl]methanamine Chemical compound NC[C@]1(C)CC=CC=C1 HYSOPXHRAHXSFM-QMMMGPOBSA-N 0.000 description 1
- HYSOPXHRAHXSFM-MRVPVSSYSA-N [(1s)-1-methylcyclohexa-2,4-dien-1-yl]methanamine Chemical compound NC[C@@]1(C)CC=CC=C1 HYSOPXHRAHXSFM-MRVPVSSYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- RQCNMAAZFRLTGZ-UHFFFAOYSA-N [2-hydroxy-4-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(OC(F)(F)F)C=C1O RQCNMAAZFRLTGZ-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- AMOODQKTVNADCO-UHFFFAOYSA-N [dimethylphosphoryloxy(methyl)phosphoryl]methane Chemical compound CP(C)(=O)OP(C)(C)=O AMOODQKTVNADCO-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- SPMAASDZPMZDCC-UHFFFAOYSA-N acetaldehyde;oxolane Chemical compound CC=O.C1CCOC1 SPMAASDZPMZDCC-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 210000005221 acidic domain Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N alpha-methylpyridine Natural products CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 229940095672 calcium sulfate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940126211 compound 54c Drugs 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- TVVHWULPVQHJLF-UHFFFAOYSA-N dimethyl 1-methylimidazole-4,5-dicarboxylate Chemical compound COC(=O)C=1N=CN(C)C=1C(=O)OC TVVHWULPVQHJLF-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- OWZFULPEVHKEKS-UHFFFAOYSA-N ethyl 2-chloro-2-oxoacetate Chemical compound CCOC(=O)C(Cl)=O OWZFULPEVHKEKS-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 125000005462 imide group Chemical group 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000006610 n-decyloxy group Chemical group 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000006609 n-nonyloxy group Chemical group 0.000 description 1
- 125000006608 n-octyloxy group Chemical group 0.000 description 1
- 125000003935 n-pentoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 125000005484 neopentoxy group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ASUOLLHGALPRFK-UHFFFAOYSA-N phenylphosphonoylbenzene Chemical group C=1C=CC=CC=1P(=O)C1=CC=CC=C1 ASUOLLHGALPRFK-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- YNCMLFHHXWETLD-UHFFFAOYSA-N pyocyanin Chemical compound CN1C2=CC=CC=C2N=C2C1=CC=CC2=O YNCMLFHHXWETLD-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000012465 retentate Substances 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- AKQXKEBCONUWCL-MRVPVSSYSA-N tert-butyl (3r)-3-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](N)C1 AKQXKEBCONUWCL-MRVPVSSYSA-N 0.000 description 1
- IHMQNZFRFVYNDS-UHFFFAOYSA-N tert-butyl n-amino-n-methylcarbamate Chemical compound CN(N)C(=O)OC(C)(C)C IHMQNZFRFVYNDS-UHFFFAOYSA-N 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- XQTUSPVIMZCNPC-UHFFFAOYSA-N thieno[3,4-c]furan-1,3-dione Chemical compound S1C=C2C(=O)OC(=O)C2=C1 XQTUSPVIMZCNPC-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Immunology (AREA)
Abstract
本公开涉及一种如式(I‑0)所示的取代杂芳酞嗪衍生物,其作为NLRP3抑制剂的用途及制备方法,其具有较好的NLRP3抑制活性。
Description
技术领域
本公开涉及医药领域,特别涉及包含化学式(I)表示的化合物或其药学上可以接受的盐的NLRP3抑制剂,其用途及制备方法。
背景技术
炎症是机体对于刺激的防御反应,包括感染性炎症和无菌型炎症。炎症主要表现为红、肿、热、痛和功能障碍,这是由血管内皮细胞通透性增加、血浆中的免疫细胞渗出导致的。组织修复后炎症反应会快速结束,但是过度的细胞因子产生会导致炎症风暴,对机体造成损伤。炎症失调是许多人类疾病的重要发病机制。
天然免疫在炎症中发挥至关重要作用。巨噬细胞、树突状细胞、上皮细胞、内皮细胞、纤维原细胞等细胞都参与天然免疫反应。天然免疫通过模式识别受体识别病原相关分子模式(pathogen-associated molecular patterns,PAMPs)和危险相关分子模式(danger-associatedmolecular patterns,DAMPs)。目前已经有五类模式识别受体被鉴定出来,包括Toll样受体(Tol-likereceptors,TLRs)、C型凝集素受体(C-typelectinreceptors,CLRs),RIG样受体(retinoic acid-inducible gene-I-like receptors,RLRs),胞内DNA感受器(cytoplasmic DNA sensors)和NOD样受体(nucleotide-bindingandoligomerization domain-like receptors,NLRs),这些模式识别受体在免疫细胞和非免疫细胞上都有表达。模式识别受体识别相应的配体之后,启动活化多种天然免疫信号通路,产生一系列促进炎症的细胞因子以及一型干扰素。
NLRs是一类胞内的模式识别受体。NLRs广泛表达在各类免疫细胞以及上皮细胞中,能够通过识别进入胞内的PAMPs和细胞压力等DAMPs启动天然免疫应答。NLRs高度的进化保守性也证明了它们在维持机体免疫稳态中至关重要。NLRs通过促进细胞因子、趋化因子的产生和抗菌相关基因的表达来调控炎症反应,因此NLRs与感染、肿瘤、自身免疫病和炎症紊乱等人类疾病密切相关。
NLRs由C端的LRR结构域、中间的NOD结构域和N端的效应结构域组成。C端的LRR结构域负责识别和结合配体,中间的NOD结构域具有dNTPase(deoxynucleosidetriphosphohydrolase)酶活性并且负责NLRs蛋白的寡聚,N端的效应结构域通过与其他蛋白相互作用发挥效应功能。目前已经发现四种N端效应结构域,分别是AD结构域(acidictransactivation domain)、BIR结构域(baculoviral inhibitory repeat-like domain)、CARD结构域(caspase activation and recruitment domain)和PYD结构域(pyrindomain)。根据N端效应结构域的不同,NOD样受体可以被分为四个亚家族,分别是NLRA亚家族(Acidic domain containing)、NLRB亚家族(BIR domain containing)、NLRC亚家族(CARD domain containing)和NLRP亚家族(pyrin domain containing)。NLRP亚家族包括14个成员,即NLRP1-14。
炎症小体是一类能够介导caspase-1活化的多聚蛋白复合物。活化的caspase-1会促进炎性细胞因子IL-1β和IL-18的加工和成熟,还会导致细胞焦亡的发生。细胞焦亡会导致更多DAMPs的释放,进一步加强免疫反应。目前已经发现8种NLRs被激活后会形成炎症小体,分别为NLRP1、NLRP2、NLRP3、NLRP6、NLRP7、NLRP12、NLRC4和NAIP。
NLRP3炎症小体由模式识别受体NLRP3、接头蛋白ASC和效应蛋白pro-caspase-1组成。NLRP3由N端的PYD结构域、中间的NACHT结构域和C端的LRR结构域组成。NLRP3炎症小体活化导致有活性的caspase-1的产生,进一步促进细胞焦亡。NLRP3炎症小体能够识别各种各样的刺激剂,包括原生动物(疟原虫、变形虫等)、病毒(腺病毒、流感病毒、仙台病毒等)、真菌(酿酒酵母、白色念珠菌等)、细菌(李斯特菌、大肠杆菌、金黄色葡萄糖菌等)。NLRP3还能识别许多内源性的DAMPs,包括尿酸结晶、ATP、胰岛淀粉样多肽、β淀粉样蛋白斑等。
另外,NLRP3炎症小体的异常激活是类风湿性关节炎、痛风性关节炎、动脉粥样硬化、心肌梗塞、帕金森综合征、阿尔兹海默症、感染性肺损伤、肺纤维化、败血症、溃疡性结肠炎、二型糖尿病、败血症、细菌性炎症、家族性地中海热、肾病综合征、心肌炎等多种人类重大疾病的重要促进因素。因此,NLRP3抑制剂在这些伴有炎症病理特征的疾病中均具有一定的治疗潜力。
发明内容
本公开的目的在于提供一种具有NLRP3抑制作用的取代杂芳酞嗪衍生物。
本公开的提供由以下化学式(I-0)表示的化合物或其药学上可以接受的盐:
其中:
n为0或1;
m选自1至5的整数;
p选自1或2;
X1、X2、X5分别独立地选自CH2、NH、CH、O、S或N;
X3、X4分别独立地选自CH2、CH或N;
R1选自氢、氘、C1-6烷基、C1-6烷氧基、C3-6环烷基、卤素、氧化膦基、羟基、氰基,所述C1-6烷基、C3-6环烷基、C1-6烷氧基、氧化膦基任选地被一个或多个卤素、C1-3烷基取代,其中,m个R1可以彼此相同或不同;
R3选自氢、氘、C1-6烷基、C1-6烷氧基、C3-6环烷基、卤素、氧化膦基、羧基、氰基,所述C1-6烷基、C1-6烷氧基、C3-6环烷基、氧化膦基任选地被一个或多个卤素、C1-3烷基取代,其中,p个R3可以彼此相同或不同;
A为单键或C1-3亚烷基链,任选地,所述C1-3亚烷基链中亚甲基上的一个或多个氢被C1-3烷基取代;
M为-NR10-、-O-或-S-
R4选自C1-6烷基、C3-9环烷基、C5-9芳基、3-9元杂环烷基、5-9元杂芳基、9-12元部分不饱和杂环双环,所述C1-6烷基、C3-9环烷基、C5-9芳基、3-9元杂环烷基、5-9元杂芳基、9-12元部分不饱和杂环双环任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、=O、-NR8R9取代;
R8、R9、R10分别独立地选自氢、C1-3烷基。
具体地,本公开涉及具有式(I)所示结构的化合物或其药学上可接受的盐,
其中:
n为0或1;
m选自1至5的整数;
p选自1或2;
X1、X2、X5分别独立地选自CH2、NH、CH、O、S或N;
X3、X4分别独立地选自CH2、CH或N;
R1选自氢、氘、C1-6烷基、C1-6烷氧基、C3-6环烷基、卤素、氧化膦基、羟基、氰基,所述C1-6烷基、C3-6环烷基、C1-6烷氧基、氧化膦基任选地被一个或多个卤素、C1-3烷基取代,其中,m个R1可以彼此相同或不同;
R3选自氢、氘、C1-6烷基、C1-6烷氧基、C3-6环烷基、卤素、氧化膦基、羧基、氰基,所述C1-6烷基、C1-6烷氧基、C3-6环烷基、氧化膦基任选地被一个或多个卤素、C1-3烷基取代,其中,p个R3可以彼此相同或不同;
A为单键或C1-3亚烷基链,任选地,所述C1-3亚烷基链中亚甲基上的一个或多个氢被C1-3烷基取代;
R4选自C1-6烷基、C3-9环烷基、C5-9芳基、3-9元杂环烷基、5-9元杂芳基、9-12元部分不饱和杂环双环,所述C1-6烷基、C3-9环烷基、C5-9芳基、3-9元杂环烷基、5-9元杂芳基、9-12元部分不饱和杂环双环任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、=O、-NR8R9取代;
R8、R9分别独立地选自氢、C1-3烷基。
优选地,R4选自C1-6烷基、C3-9环烷基、C5-9芳基、3-9元杂环烷基、5-9元杂芳基、9-12元部分不饱和杂环双环,所述C1-6烷基、C3-9环烷基、C5-9芳基、3-9元杂环烷基、5-9元杂芳基、9-12元部分不饱和杂环双环任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、-NR8R9取代。
优选地,R1选自C1-3烷基、C1-3烷氧基、C3-6环烷基、氧化膦基、羟基、氰基、卤素,所述C1-3烷基、C1-3烷氧基、C3-6环烷基、氧化膦基任选地被一个至三个卤素、C1-3烷基取代。
优选地,R1选自C1-3烷基、C1-3烷氧基、羟基、氰基、卤素、氧化膦基,所述C1-3烷基、C1-3烷氧基、氧化膦基任选地被一个至三个氟、甲基取代。
优选地,R1选自三氟甲基、二氟甲基、甲基、氟、羟基、二甲基氧化膦基或三氟甲氧基。
优选地,R1选自三氟甲基、甲基、氟、羟基、二甲基氧化膦基或三氟甲氧基。
优选地,R1选自三氟甲基、甲基或羟基。
优选地,R3选自氢、C1-3烷基、C3-6环烷基、C1-3烷氧基、卤素、氧化膦基,所述C1-3烷基、C1-3烷氧基、C3-6环烷基、氧化膦基任选地被一个至三个卤素、C1-3烷基取代。
优选地,R3选自C1-3烷基、C1-3烷氧基、C3-6环烷基、氧化膦基,所述C1-3烷基、C1-3烷氧基、C3-6环烷基、氧化膦基任选地被一个至三个氟、甲基取代。
优选地,R3选自氢、甲基、甲氧基、环丙烷基、乙基、氟、三氟甲基或二甲基氧化膦基。
优选地,R3选自氢、甲基、甲氧基。
优选地,A为单键或C1-3亚烷基链,任选地,所述C1-3亚烷基链中亚甲基上的一个或多个氢被甲基取代。
优选地,A为单键、-CH2-、-(CH3)CH-、-CH2CH2-。
优选地,A为单键。
优选地,R4选自C1-6烷基、C5-8环烷基、苯基、含有1-2个分别独立地选自N、O、S原子的5-7元杂环烷基、含有1-2个分别独立地选自N、O、S原子的5-7元杂芳基、含有1-2个分别独立地选自N、O、S原子的9-12元部分不饱和杂环双环,所述C1-6烷基、C5-8环烷基、苯基、含有1-2个分别独立地选自N、O、S原子的5-7元杂环烷基、含有1-2个分别独立地选自N、O、S原子的5-7元杂芳基、含有1-2个分别独立地选自N、O、S原子的9-12元部分不饱和杂环双环任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、卤代C1-3烷基、=O、-NR8R9取代。
优选地,R4选自C1-6烷基、C5-8环烷基、苯基、含有1-2个分别独立地选自N、O、S原子的5-7元杂环烷基、含有1-2个分别独立地选自N、O、S原子的5-7元杂芳基、含有1-2个分别独立地选自N、O、S原子的9-12元部分不饱和杂环双环,所述C1-6烷基、C5-8环烷基、苯基、含有1-2个分别独立地选自N、O、S原子的5-7元杂环烷基、含有1-2个分别独立地选自N、O、S原子的5-7元杂芳基、含有1-2个分别独立地选自N、O、S原子的9-12元部分不饱和杂环双环任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、-NR8R9取代。
优选地,R4选自C1-6烷基、C5-8环烷基、苯基、含有1-2个分别独立地选自N、O原子的5-7元杂环烷基、含有1个N原子的5-7元杂芳基、含有1个N原子的9-12元部分不饱和杂环双环,所述C1-6烷基、C5-8环烷基、苯基、含有1-2个分别独立地选自N、O原子的5-7元杂环烷基、含有1个N原子的5-7元杂芳基、含有1个N原子的9-12元部分不饱和杂环双环任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、卤代C1-3烷基、=O、-NR8R9取代。
优选地,R4选自C1-6烷基、C5-8环烷基、苯基、含有1-2个分别独立地选自N、O原子的5-7元杂环烷基、含有1个N原子的5-7元杂芳基、含有1个N原子的9-12元部分不饱和杂环双环,所述C1-6烷基、C5-8环烷基、苯基、含有1-2个分别独立地选自N、O原子的5-7元杂环烷基、含有1个N原子的5-7元杂芳基、含有1个N原子的9-12元部分不饱和杂环双环任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、-NR8R9取代。
优选地,R4选自正丁基、环己基、苯基、哌啶基、吡啶基、吡咯基、吡咯烷基、吗啉基、四氢吡喃基、所述环己基、苯基、哌啶基、吡啶基、吡咯基、吡咯烷基任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、卤代C1-3烷基、=O、-NR8R9取代。
优选地,R4选自正丁基、环己基、苯基、哌啶基、吡啶基、吡咯基、吡咯烷基、吗啉基、所述环己基、苯基、哌啶基、吡啶基、吡咯基、吡咯烷基任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、-NR8R9取代。
优选地,R4选自正丁基、环己基、苯基、哌啶基、吡啶基、吡咯烷基、吗啉基、四氢吡喃基、所述环己基、苯基、哌啶基、吡啶基、吡咯烷基任选地被一个至二个氟、羟基、甲基、乙基、乙酰基、卤代C1-3烷基、=O、-N(CH3)2取代。
优选地,R8、R9为甲基。
本公开涉及具有式(II)所示结构的化合物或其药学上可接受的盐:
其中:
n、X1、X2、X3、X4、X5、R3、R4、A的定义如前述的定义。
优选地,R11选自氢、氘、C1-6烷基、C1-6烷氧基、C3-6环烷基、卤素、氧化膦基,所述C1-6烷基、C3-6环烷基、C1-6烷氧基、氧化膦基任选地被一个或多个卤素、C1-3烷基取代。
优选地,R11选自氢、C1-3烷基、C1-3烷氧基、氧化膦基、卤素、C3-6环烷基,所述C1-3烷基、C1-3烷氧基、C3-6环烷基、氧化膦基任选地被一个至三个卤素、C1-3烷基取代。
优选地,R11选自氢、C1-3烷基、C1-3烷氧基、卤素、氧化膦基,所述C1-3烷基、C1-3烷氧基、氧化膦基任选地被一个至三个氟、甲基取代。
优选地,R11选自氢、三氟甲基、甲基、氟、二甲基氧化膦基或三氟甲氧基。
优选地,R11选自三氟甲基、甲基、三氟甲氧基、氟。
R2选自氢、氘、C1-6烷基、羟基、卤素、氰基、二氟甲基。
优选地,R2选自氢、氘、C1-6烷基、羟基、卤素、氰基。
优选地,R2选自羟基、二氟甲基。
优选地,R2选自羟基。
R5、R6、R7分别独立地选自氢、卤素、C1-3烷基。
优选地,R5、R6、R7分别独立地选自氢、氟、甲基。
本公开涉及具有式(III)所示结构的化合物或其药学上可接受的盐:
其中:
n、X1、X2、R11、R3、R4、A如前述的定义。
本公开涉及具有式(IV)所示结构的化合物或其药学上可接受的盐:
其中:
X1、X2、R11、R3、R4、A如前述的定义。
本公开涉及具有式(IVa)、(IVb)、(IVc)、(IVd)或(IVe)所示结构的化合物或其药学上可接受的盐:
其中:
R1、R3、R4、A如前述的定义。
本公开还涉及具有式(V)或式(VI)所示的化合物或其药学上可接受的盐:
其中:
R3、R4、A如前述的定义。本公开涉及具有式(I-1)所示的化合物或其药学上可接受的盐:
其中:
n为0或1;
m选自1至5的整数;
p选自1或2;
X1、X2、X5、X6分别独立地选自CH2、NH、CH、O、S或N;
X3、X4分别独立地选自CH2、CH或N;
R1选自氢、氘、C1-6烷基、C1-6烷氧基、C3-6环烷基、卤素、氧化膦基、羟基、氰基,所述C1-6烷基、C3-6环烷基、C1-6烷氧基、氧化膦基任选地被一个或多个卤素、C1-3烷基取代,其中,m个R1可以彼此相同或不同;
R3选自氢、氘、C1-6烷基、C1-6烷氧基、C3-6环烷基、卤素、氧化膦基、羧基、氰基,所述C1-6烷基、C1-6烷氧基、C3-6环烷基、氧化膦基任选地被一个或多个卤素、C1-3烷基取代,其中,p个R3可以彼此相同或不同;
A为单键或C1-3亚烷基链,任选地,所述C1-3亚烷基链中亚甲基上的一个或多个氢被C1-3烷基取代;
R4选自C1-6烷基、C3-9环烷基、C5-9芳基、3-9元杂环烷基、5-9元杂芳基、9-12元部分不饱和杂环双环,所述C1-6烷基、C3-9环烷基、C5-9芳基、3-9元杂环烷基、5-9元杂芳基、9-12元部分不饱和杂环双环任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、=O、-NR8R9取代;
R8、R9分别独立地选自氢、C1-3烷基;
优选地,所述X6选自S。
本公开涉及下列化合物或其药学上可接受的盐:
本公开涉及上述化合物或其药学上可接受的盐的制备方法,所述方法包括以下步骤:
步骤一:将化合物A0溶于POCl3中,加热到100℃反应过夜,TLC确定反应完全,将反应液直接浓缩,除掉POCl3后,将油状粗品慢慢滴加入冰水中,乙酸乙酯萃取,经过柱层析分离得到目标化合物A1;
步骤二:将化合物A1,相应的胺,Na2CO3溶于干燥DMF中,此混合体系置于封管中加热到120度反应过夜,TLC确定原料转化完全,将反应液加入到水中,乙酸乙酯萃取,经过柱层析分离得到目标化合物A2;
步骤三:将化合物A2,硼酸,碳酸钠和Pd(dppf)Cl2加入到二氧六环和水的混合溶剂中,氮气置换3次,加热到110℃反应3小时。将反应液加入到水中,乙酸乙酯萃取,经过柱层析分离得到目标化合物I-0。
在一个实施方案中,所述方法包括以下步骤:
步骤一:将化合物A0’溶于POCl3中,加热到100℃反应过夜,TLC确定反应完全,将反应液直接浓缩,除掉POCl3后,将油状粗品慢慢滴加入冰水中,乙酸乙酯萃取,经过柱层析分离得到目标化合物A1’;
步骤二:将化合物A1’,相应的'胺,Na2CO3溶于干燥DMF中,此混合体系置于封管中加热到120度反应过夜,TLC确定原料转化完全,将反应液加入到水中,乙酸乙酯萃取,经过柱层析分离得到目标化合物A2’;
步骤三:将化合物A2’,硼酸,碳酸钠和Pd(dppf)Cl2加入到二氧六环和水的混合溶剂中,氮气置换3次,加热到110℃反应3小时。将反应液加入到水中,乙酸乙酯萃取,经过柱层析分离得到目标化合物II。
本公开的另一方面,提供前述任一种的化合物的立体异构体、溶剂化物或其前药。
本公开涉及一种药物组合物,所述组合物包含上述任一种化合物或其药学上可接受的盐和药学上可接受的辅料。
本公开涉及上述任一种的化合物或其药学上可接受的盐、上述药物组合物在制备治疗NLRP3介导的病症的药物的应用。
本公开涉及上述任一种的化合物或其药学上可接受的盐、上述药物组合物在制备抑制NLRP3抑制剂中的应用。
本公开涉及一种抑制有需要的患者中的NLRP3的方法,其包含向所述患者施用上述任一种的化合物或其药学上可接受的盐、上述药物组合物。
本公开涉及一种用于治疗有需要的患者的由NLRP3介导的病症的方法,其包含向所述患者施用上述任一种的化合物或其药学上可接受的盐、上述药物组合物,优选地,所述NLRP3介导的病症包括但不限于类风湿性关节炎、痛风性关节炎、动脉粥样硬化、心肌梗塞、帕金森综合征、阿尔兹海默症、感染性肺损伤、肺纤维化、败血症、溃疡性结肠炎、二型糖尿病、败血症、细菌性炎症、家族性地中海热、肾病综合征、心肌炎。
本公开的另一方面,提供包含前述任一种的化合物或其药学上可接受的盐、药物组合物的NLRP3抑制剂在治疗心脏疾病方面的用途。
本公开的另一方面,提供包含前述任一种的化合物或其药学上可接受的盐、药物组合物的NLRP3抑制剂在治疗炎性病症方面的用途。
本公开的另一方面,提供包含前述任一种的化合物或其药学上可接受的盐、药物组合物的NLRP3抑制剂在治疗感染性疾病方面的用途。
本公开的化合物具有NLRP3抑制作用。
具体实施方式
I.定义
根据本公开的上述内容,按照本领域的普通技术知识和惯用手段,在不脱离本公开上述基本技术思想前提下,还可以做出其它多种形式的修改、替换或变更。
除非另有其它明确表示,否则在整个说明书和权利要求书中,术语“包括”或其变换如“包含”或“包括有”等等将被理解为包括所陈述的元件或组成部分,而并未排除其它元件或其它组成部分。
本公开化合物可以是不对称的,例如,具有一个或多个立体异构体。除非另有说明,所有立体异构体都包括,如对映异构体和非对映异构体。本公开的含有不对称碳原子的化合物可以以光学活性纯的形式或外消旋形式被分离出来。光学活性纯的形式可以从外消旋混合物拆分,或通过使用手性原料或手性试剂合成。外消旋体、非对映异构体、对映异构体都包括在本公开的范围之内。
在本公开中,数字范围是指给定范围中的各个整数。例如,“C1-6”是指该基团可具有1个碳原子、2个碳原子、3个碳原子、4个碳原子、5个碳原子或6个碳原子;“C1-3”是指该基团可具有1个碳原子、2个碳原子或3个碳原子。
术语“任选”或“任选地”是指随后描述的事件或情况可能发生或可能不发生,该描述包括发生所述事件或情况和不发生所述事件或情况。
术语“被取代的”或“取代”是指特定原子或基团上的任意一个或多个氢原子被取代基取代,只要特定原子或基团的价态是正常的并且取代后的化合物是稳定的。当取代基为酮基(即=O)时,意味着两个氢原子被取代。除非另有规定,取代基的种类和数目在化学上可以实现的基础上可以是任意的。取代基可以选自以下的一个、两个或更多个取代基取代:氘、卤素基团、氰基、硝基、-C(=O)R、-C(=O)OR’、-OC(=O)R”、酰亚胺基、酰胺基、羟基、经取代或未经取代的胺基、经取代或未经取代的烷基、经取代或未经取代的环烷基、经取代或未经取代的卤代烷基、经取代或未经取代的烷氧基、经取代或未经取代的烯基、经取代或未经取代的炔基、经取代或未经取代的芳基、经取代或未经取代的芳氧基、经取代或未经取代的杂芳基等,但不限于此。
当任何变量(例如Rn)在化合物的组成或结构中出现一次以上时,其在每一种情况下的定义都是独立的。因此,例如,如果一个基团被一个至三个R所取代,则所述基团可以任选地至多被三个R所取代,并且每种情况下的R都有独立的选项。此外,取代基和/或其变体的组合只有在这样的组合会产生稳定的化合物的情况下才是被允许的。
术语“烷基”指饱和的脂族烃基团,包括直链的或支链的饱和烃基,所述烃基具有所示出的碳原子数。如术语“C1-6烷基”包括C1烷基、C2烷基、C3烷基、C4烷基、C5烷基、C6烷基,实例包括,但不限于,甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、正戊基、2-戊基、3-戊基、正己基、2-己基、3-己基等。其可以是二价的,例如亚甲基、亚乙基。
术语“烷氧基”可以为直链、支化或环状的。烷氧基的碳原子数没有特别限制,但优选为1至20。其具体实例包括甲氧基、乙氧基、正丙氧基、异丙氧基(isopropoxy)、异丙基氧基(i-propyloxy)、正丁氧基、异丁氧基、叔丁氧基、仲丁氧基、正戊氧基、新戊氧基、异戊氧基、正己氧基、3,3-二甲基丁氧基、2-乙基丁氧基、正辛氧基、正壬氧基、正癸氧基等,但不限于此。
术语“氧化膦基”为-P(=O)(Rm)(Rn)的结构,其中Rm和Rn彼此相同或不同,并且各自独立地为氢、氘、经取代或未经取代的烷基、经取代或未经取代的芳基或经取代或未经取代的杂芳基,氧化膦基的具体实例包括烷基氧化膦基、芳基氧化膦基等,更具体地,包括二苯基氧化膦基、二萘基氧化膦基团等,但不限于此。
术语“亚烷基”或“亚烷基链”是指完全饱和的直链或支链二价烃链基团,并且具有一至十二个碳原子,通常可表示为C1-C12亚烷基。优选的亚烷基为C1-C6亚烷基,更优选为C1-C4亚烷基。C1-C12亚烷基的非限制性实例包括亚甲基、亚乙基、亚丙基、亚正丁基、亚乙烯基、亚丙烯基、亚正丁烯基、亚丙炔基、亚正丁炔基等。亚烷基链通过单键连接至分子的其余部分并且通过单键连接至所述基团。亚烷基链连接至分子的其余部分和连接至所述基团的点可通过所述链内的一个碳或任何两个碳。除非本说明书中另外特别地规定,否则亚烷基链可任选地被取代。
在本公开中,卤素基团的实例可以包括氟、氯、溴或碘。
在本公开中,术语“环烷基”是指单环饱和烃体系,无杂原子和双键。例如,术语“C3-9环烷基”的实例包括,但不限于,环丙基、环丁基、环戊基、环己基、环庚基、环辛基、环壬基。
在本公开中,术语“芳基”是指具有共轭的π电子体系的全碳单环或稠合多环的芳香环基团,其通过从母体芳香环体系的单一碳原子上除去一个氢原子而得到。其包括包含与饱和、部分不饱和的环,或芳香碳环稠合的芳环的双环基团。其具体实例包括苯基或萘基,但不限于此。
在本公开中,术语“杂环烷基”是指具有环碳原子和1至2个环杂原子的5-12元饱和非芳香体系。杂环基的具体实例包括哌啶基或四氢吡咯基,但不限于此。
在本公开中,术语“杂芳基”指包含至少一个独立地选自氮、氧和硫杂原子的一价芳基,杂芳基可为单环,也可以为多环体系,例如二环,其中两个或两个以上的环以并环、桥环或螺环形式存在,其中至少一个环含有一个或多个杂原子。杂芳基的具体实例包括吡啶基、噻吩基、咪唑基、嘧啶基、吡啶基、呋喃基、吡嗪基、噻唑基、喹啉基、异喹啉基、吲哚基、苯并咪唑基、咪唑并吡啶基、苯并呋喃基、哒嗪基、异吲哚基,但不限于此。
术语“杂环”是指具有环碳原子和1至2个环杂原子的5-12元饱和非芳香体系,其中杂原子独立地选自氮、硫或氧原子。在含有一或多个氮原子的杂环基团中,连接点可为碳或氮原子,只要原子价容许。杂环可为单环或多环体系,例如二环,其中两个或两个以上的环以并环、桥环或螺环形式存在,其中至少一个环含有一个或多个杂原子。
如本文所用,术语“部分不饱和”是指包括至少一个双键或三键的环部分。术语“部分不饱和”意图涵盖具有多个不饱和位点的环,但并不意图包括如本文所定义的芳基或杂芳基部分。
药物或药物组合物
术语“药学上可接受的”是指在合理的医学判断的范围内适合用于与人类和动物的组织接触而没有,与合理利益/风险比相称的,过度毒性、刺激、过敏反应或其它问题或并发症的那些化合物、材料、组合物和/或剂型。
术语“药学上可接受的盐”是指保留了特定化合物的游离酸和碱的生物学效力而没有生物学不良作用的盐。例如酸(包括有机酸和无机酸)加成盐或碱加成盐(包括有机碱和无机碱)。
本公开的药学上可接受的盐可由含有酸根或碱基的母体化合物通过常规化学方法合成。一般情况下,这样的盐的制备方法是:在水或有机溶剂或两者的混合物中,经由游离酸或碱形式的这些化合物与化学计量的适当的碱或酸反应来制备。
本公开的药物或药物组合物可以经口地、局部地、肠胃外地或粘膜地(例如,含服地、通过吸入或直肠地)以包含常规的非-毒性药学可接受的载体的剂量单位配制剂施用。
对于以片剂或胶囊形式的口服给药,活性药物组分可以与非-毒性的、药学可接受的辅料如粘结剂(例如,预胶化的玉米淀粉、聚乙烯吡咯烷酮或羟丙基甲基纤维素);填料(例如,乳糖、蔗糖、葡萄糖、甘露糖醇、山梨糖醇和其它还原性和非-还原性糖类、微晶纤维素、硫酸钙或磷酸氢钙);润滑剂(例如,硬脂酸镁、滑石粉或硅土、硬脂酸、硬脂基富马酸酯钠、甘油二十二烷酸酯、硬脂酸钙等);崩解剂(例如,马铃薯淀粉或羟乙酸淀粉钠);或润湿剂(例如,月桂基硫酸钠)、着色剂和调味剂、明胶、甜味剂、天然和合成的胶(如***胶、黄蓍胶或藻朊酸盐)、缓冲盐、羧甲纤维素、聚乙二醇、蜡、等。对于以液体形式的口服给药,所述药物组分可以与非-毒性、药学可接受的惰性载体(例如,乙醇、甘油、水)、防沉降剂(例如,山梨糖醇糖浆、纤维素衍生物或氢化的可食用脂肪)、乳化剂(例如,卵磷脂或***胶)、非-水性载体(例如,扁桃油、油酯类、乙醇或经分馏的植物油)、保藏剂(例如,p-羟基苯甲酸甲酯或p-羟基苯甲酸丙酯或山梨酸)等组合。还可以加入稳定剂如抗氧化剂(BHA、BHT、桔酸丙酯、抗坏血酸钠、柠檬酸)以稳定所述剂型。
包含作为活性化合物的片剂可以通过本领域熟知的方法包衣。包含作为活性化合物的式I化合物的本公开的所述组合物还可以引入小珠、微球或微胶囊,例如由聚乙醇酸/乳酸(PGLA)构建的。用于口服给药的液体的制剂可以采取例如溶液,糖浆剂,乳液或混悬液的形式或者它们可以呈现为在使用前用水或其它适宜的辅料重构的干产品。用于口服给药的制剂可以适宜地配制以使活性化合物受控或延迟地释放。
本公开的药物或药物组合物可以经肠胃外递送,即,通过静脉内(i.v.)、脑室内(i.c.v.)、皮下(s.c.)、腹膜内(i.p.)、肌内(i.m.)、皮下(s.d.)或皮内(i.d.)施用,通过直接注射,经例如快速浓注或连续输液。用于注射的配制剂可以单位剂型呈现,例如在具有添加的保藏剂的安瓿瓶或多-剂量容器中。所述组合物可以采用赋形剂(excipient)的形状,在油或水性载体中的混悬液、溶液或乳液的形式,并可以包含配制试剂如防沉降剂、稳定剂和/或分散剂。备选地,所述活性成分可以以粉末形式在使用前用适宜的载体(例如无菌无热原水)重构。
本公开的药物或药物组合物还可以配制用于直肠给药,例如呈栓剂或保留灌肠(例如,包含常规栓剂基质如可可油或其它甘油酯)。
术语“治疗”包括抑制、缓解、预防或消除与所治疗的疾病、病症或失调相关的一种或多种症状或副作用。
术语“减少”、“抑制”、“减轻”或“减小”的使用是相对于对照的。本领域技术人员将容易地确定用于每个实验的适当对照。例如,将用化合物处理的受试者或细胞中的降低了的反应与未用化合物处理的受试者或细胞中的反应进行比较。
如本文所用,术语“有效量”或“治疗有效量”是指足以治疗、抑制或减轻被治疗的疾病状态的一种或多种症状或以其它方式提供期望的药理学和/或生理学作用的剂量。精确的剂量将根据多种因素而变化,如受试者依赖的变量(例如,年龄、免疫***健康等)、疾病或病,以及所施用的治疗。有效量的效果可以相对于对照。这些对照在本领域中是已知的并且在本文中讨论,并且可以是例如在药物或药物组合施用之前或没有施用时的受试者的状况,或在药物组合的情况下,可以将组合效果与仅施用一种药物的效果进行比较。
术语“赋形剂”在本文中用于包括可以包含在微粒中或其上的不是治疗或生物活性化合物的任何其它化合物。因此,赋形剂应当是药学上或生物学上可接受的或相关的,例如赋形剂通常对受试者无毒性。“赋形剂”包括单一的这种化合物,并且还旨在包括多种化合物。
术语“药物组合物”意指包含本公开所述化合物或其药学上可接受的盐,以及依施用方式和剂型的性质而定的至少一种选自以下药学上可接受的成分的组合物,包括但不限于:载体、稀释剂、佐剂、赋形剂、防腐剂、填充剂、崩解剂、润湿剂、乳化剂、悬浮剂、甜味剂、矫味剂、香味剂、抗菌剂、抗真菌剂、润滑剂、分散剂、温敏材料、温度调节剂、黏附剂、稳定剂、助悬剂等。
用途和治疗方法
术语“患者”、“对象”、“个体”等等在本文中可交换使用,并指的是服从本文描述方法的任何动物或其细胞,不论是体外或原位。在一些非限制性实施方式中,患者、对象或个体为人。
根据本公开的方法,化合物或组合物可用于有效治疗与NRLP3相关的疾病或减轻其严重程度的任何量和任何施用途径施用。
本公开涉及一种抑制生物样品中的NRLP3的方法,其包含使所述生物样品与本公开的化合物或包含所述化合物的组合物接触的步骤。
术语“生物样品”包括(但不限于)细胞培养物或其提取物;从哺乳动物获得的活检材料或其提取物;以及血液、唾液、尿液、粪便、***、泪液或其它体液或其提取物。生物样品中的酶的激动可用于达成本领域的技术人员已知的多种目的。此类目的的实例包括(但不限于)生物分析、基因表达研究和生物目标鉴别。
本公开的抑制患者中的NRLP3的方法,其包含向所述患者施用本公开的化合物或包含所述化合物的组合物的步骤。
所提供的化合物为NRLP3抑制剂,因此可用于治疗一或多种与NRLP3活性相关的病症。因此,在某些实施例中,本公开提供了一种用于治疗NRLP3介导的病症的方法,其包含向有需要的患者施用本公开的化合物或其药学上可接受的组合物的步骤。
如本文所用,术语“由NRLP3介导”的病症、疾病和/或病状如本文所用意指已知NRLP3或其突变体起作用的任何疾病或其它有害病状。因此,本公开的另一实施例涉及治疗已知NRLP3或其突变体起作用的一或多种疾病或减轻其严重程度。
联合治疗方法
本公开提供了使用如本公开所述的化合物与其他治疗药物的联合疗法。本公开所用的“联合疗法”一词包括以顺序方式施用这些药剂,即其中每种治疗剂在不同时间施用,以及施用这些治疗剂,或至少二种药剂,基本上同时进行。每种试剂的顺序,或基本上同时给药,可受任何适当途径的影响,包括,但不限于,口服途径、静脉内途径、肌肉内、皮下途径,以及通过黏膜组织的直接吸收。药剂可以通过相同的途径或不同的途径来施用。例如,可以口服给予第一药剂,而以静脉内施用第二药剂。此外,选择的组合剂可通过静脉内注射施用,而组合的其它药剂可以口服给药。或者,例如,可以通过静脉内或皮下注射施用二种或更多种药剂。
II.实施例
下面参照实施例进一步阐释本公开。对本公开的具体示例性实施方案的描述是为了说明和例证的目的。这些描述并非想将本公开限定为所公开的精确形式,并且很显然,根据本申请说明书的教导,可以进行很多改变和变化。对示例性实施例进行选择和描述的目的在于解释本公开的特定原理及其实际应用,从而使得本领域的技术人员能够实现并利用本公开的各种不同的示例性实施方案以及各种不同的选择和改变。
下述实施例中所使用的实验方法如无特殊说明,均为常规方法。
下述实施例中所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
实施例1:(R)-2-(4-((1-甲基哌啶-3-基)胺)酞嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物苯酐(1a)(1.0g,6.75mmol),N2H4.H2O(1.01g,20.25mmol)溶于醋酸(20mL)中,加热到120℃回流过夜。TLC确定反应完全,将反应液直接浓缩干后加水(20ml)分散固体,过滤,滤饼抽干后真空干燥过夜,得到目标化合物1b(2,3-二氢邻苯二甲嗪-1,4-二酮)(0.75g,产率:68.51%,LCMS m/z=163.2[M+1]+)。
步骤二:将化合物(1b)(0.20g,1.23mmol)溶于POCl3(2mL)中,加热到100℃反应过夜。TLC确定反应完全,将反应液直接浓缩,除掉POCl3后,将油状粗品慢慢滴加入冰水中(20ml),充分搅拌,用2N氢氧化钠水溶液调节PH=8,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=20:1)得到目标化合物1c(1,4-二氯酞嗪)(0.21g,产率:85.54%,LCMS m/z=199.2[M+1]+)。
步骤三:将化合物(1c)(0.20g,1.00mmol),(R)-1-甲基哌啶-3-胺(0.126g,1.11mmol),Na2CO3(0.21g,2.01mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(1d)((R)-4-氯-N-(1-甲基哌啶-3-基)酞嗪-1-胺)(0.06g,产率:21.57%,LCMS m/z=277.2[M+1]+)。
步骤四:将化合物(1d)(0.05g,0.18mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(0.045g,0.217mmol),碳酸钠(0.04g,0.36mmol)和Pd(dppf)Cl2(15.00mg,0.02mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到化合物1((R)-2-(4-((1-甲基哌啶-3-基)胺)酞嗪-1-基)-5-(三氟甲基)苯酚)(0.01g,产率:13.76%,LCMS m/z=403.2[M+1]+)。
实施例2:(R)-2-(4-((1-甲基哌啶-3-基)氨基)-5,6,7,8-四氢邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物4,5,6,7-四氢异苯并呋喃-1,3-二酮(2a)(1.0g,6.57mmol),N2H4.H2O(0.98g,19.72mmol)溶于醋酸(20mL)中,加热到120℃回流过夜。TLC确定反应完全,将反应液直接浓缩干后加水(20ml)分散固体,过滤,滤饼抽干后真空干燥过夜,得到目标化合物2b(2,3,5,6,7,8-六氢酞嗪-1,4-二酮)(0.60g,产率:54.93%,LCMS m/z=167.2[M+1]+)。
步骤二:将化合物(2b)(0.20g,1.20mmol)溶于POCl3(2mL)中,加热到100度反应过夜。TLC确定反应完全,将反应液直接浓缩,除掉POCl3后,将油状物粗品慢慢滴加入冰水中(20ml),充分搅拌,用2N氢氧化钠水溶液调节PH=8,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=20:1)得到目标化合物(2c)(1,4-二氯-5,6,7,8-四氢邻苯二甲嗪)(0.15g,产率:61.38%,LCMS m/z=204.2[M+1]+)。
步骤三:将化合物(2c)(0.15g,0.738mmol),(R)-1-甲基哌啶-3-胺(0.093g,0.81mmol),Na2CO3(0.16g,1.48mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(2d)((R)-4-氯-N-(1-甲基哌啶-3-基)-5,6,7,8-四氢邻苯二嗪-1-胺)(0.05g,产率:24.11%,LCMS m/z=281.2[M+1]+)。
第四步:将化合物(2d)(0.05g,0.18mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(0.044g,0.214mmol),碳酸钠(0.037g,0.36mmol)和Pd(dppf)Cl2(15.00mg,0.02mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物2((R)-2-(4-((1-甲基哌啶-3-基)氨基)-5,6,7,8-四氢邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚)(0.011g,产率:15.20%,LCMS m/z=407.2[M+1]+)。
实施例3:(R)-2-(7-甲基-4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物4-甲基苯酐(3a)(2.0g,12.33mmol),N2H4.H2O(1.85g,37.00mmol)溶于醋酸(30mL)中,加热到120℃回流过夜。TLC确定反应完全,将反应液直接浓缩干后加水(20ml)分散固体,过滤,滤饼抽干后真空干燥过夜,得到目标化合物3b(6-甲基-2,3-二氢邻苯二甲嗪-1,4-二酮)(1.51g,产率:69.03%,LCMS m/z=177.2[M+1]+)。
步骤二:将化合物(3b)(1.51g,8.57mmol)溶于POCl3(10mL)中,加热到100℃反应过夜。TLC确定反应完全,将反应液直接浓缩,除掉POCl3后,将油状物粗品慢慢滴加入冰水中(50ml),充分搅拌,用2N氢氧化钠水溶液调节PH=8,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=10:1)得到目标化合物(3c)(1,4-二氯-6-甲基邻苯二甲嗪)(1.45g,产率:79.40%,LCMS m/z=213.2[M+1]+)。
步骤三:将化合物(3c)(0.20g,0.94mmol),(R)-1-甲基哌啶-3-胺(0.12g,1.04mmol),Na2CO3(0.20g,1.89mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(3d)与(4d)的混合物(0.08g,产率:29.31%,LCMS m/z=291.2[M+1]+)。
步骤四:将化合物(3d)与(4d)混合物(0.08g,0.27mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(0.074g,0.357mmol),碳酸钠(0.058g,0.55mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物PTLC分离(DCM:CH3OH=10:1)得到目标化合物3((R)-2-(7-甲基-4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚)(0.011g,产率:8.73%,LCMS m/z=417.2[M+1]+)。
实施例4:(R)-2-(6-甲基-4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(3c)(0.20g,0.94mmol),(R)-1-甲基哌啶-3-胺(0.12g,1.04mmol),Na2CO3(0.20g,1.89mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(4d)与(3d)的混合物(0.08g,产率:29.31%,LCMS m/z=291.2[M+1]+)。
步骤二:将化合物(3d)与(4d)混合物(0.08g,0.27mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(0.074g,0.357mmol),碳酸钠(0.058g,0.55mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物PTLC分离(DCM:CH3OH=10:1)得到目标化合物4((R)-2-(6-甲基-4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚)(0.008g,产率:6.98%,LCMS m/z=417.2[M+1]+)。
实施例5:(R)-2-(7-甲氧基-4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物4-甲氧基苯酐(5a)(2.0g,11.23mmol),N2H4.H2O(1.69g,33.68mmol)溶于醋酸(30mL)中,加热到120度回流过夜。TLC确定反应完全,将反应液直接浓缩干后加水(20ml)分散固体,过滤,滤饼抽干后真空干燥过夜,得到目标化合物5b(6-甲氧基-2,3-二氢邻苯二甲嗪-1,4-二酮)(1.42g,产率:65.82%,LCMS m/z=193.2[M+1]+)。
步骤二:将化合物(5b)(1.42g,7.39mmol)溶于POCl3(10mL)中,加热到100度反应过夜。TLC确定反应完全,将反应液直接浓缩,除掉POCl3后,将油状物粗品慢慢滴加入冰水中(50ml),充分搅拌,用2N氢氧化钠水溶液调节PH=8,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=10:1)得到目标化合物(5c)(1,4-二氯-6-甲氧基邻苯二甲嗪)(1.20g,产率:70.90%,LCMS m/z=229.2[M+1]+)。
步骤三:将化合物(5c)(0.20g,0.87mmol),(R)-1-甲基哌啶-3-胺(0.11g,0.96mmol),Na2CO3(0.20g,1.89mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(5d)与(6d)的混合物(0.09g,产率:33.60%,LCMS m/z=307.2[M+1]+)。
第四步:将化合物(5d)与(6d)混合物(0.09g,0.29mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(78.53mg,0.38mmol),碳酸钠(62.18mg,0.58mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物PTLC分离(DCM:CH3OH=10:1)得到目标化合物5((R)-2-(7-甲氧基-4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚)(0.01g,产率:7.88%,LCMS m/z=433.2[M+1]+)。
实施例6:(R)-2-(6-甲氧基-4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
第一步:将化合物(5c)(0.20g,0.87mmol),(R)-1-甲基哌啶-3-胺(0.11g,0.96mmol),Na2CO3(0.20g,1.89mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(6d)与(5d)的混合物(0.09g,产率:33.60%,LCMS m/z=307.2[M+1]+)。
第二步:将化合物(5d)与(6d)混合物(0.09g,0.29mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(78.53mg,0.38mmol),碳酸钠(62.18mg,0.58mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物PTLC分离(DCM:CH3OH=10:1)得到目标化合物6((R)-2-(6-甲氧基-4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚)(0.008g,产率:6.31%,LCMS m/z=433.2[M+1]+)。
实施例7:(R)-2-(4-((1-苯基乙基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(1c)(0.20g,1.00mmol),(R)-1-甲基苄胺(0.15g,1.21mmol),Na2CO3(0.21g,2.01mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=3:1)得到目标化合物(7a)((R)-4-氯-N-(1-苯乙基)邻苯二氮嗪-1-胺(7a))(0.14g,产率:49.10%,LCMS m/z=284.2[M+1]+)。
步骤二:将化合物(7a)(0.05g,0.17mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(39.91mg,0.19mmol),碳酸钠(37.35mg,0.35mmol)和Pd(dppf)Cl2(10.24mg,0.014mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=3:1)得到目标化合物7((R)-2-(4-((1-苯基乙基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚)(0.02g,产率:27.72%,LCMS m/z=410.2[M+1]+)。
实施例8:(S)-2-(4-((1-苯基乙基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(1c)(0.20g,1.00mmol),(S)-1-甲基苄胺(0.15g,1.21mmol),Na2CO3(0.21g,2.01mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=3:1)得到目标化合物(8a)((S)-4-氯-N-(1-苯乙基)邻苯二氮嗪-1-胺)(0.14g,产率:49.10%,LCMS m/z=284.2[M+1]+)。
步骤二:将化合物(8a)(0.05g,0.17mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(39.91mg,0.19mmol),碳酸钠(37.35mg,0.35mmol)和Pd(dppf)Cl2(10.24mg,0.014mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=3:1)得到目标化合物8((S)-2-(4-((1-苯基乙基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚)(0.02g,产率:27.72%,LCMS m/z=410.2[M+1]+)。
实施例9:(R)-2-(4-((1-(4-氟苯基)乙基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(1c)(0.20g,1.00mmol),(R)-1-(4-氟苯基)乙烷-1-胺(0.16g,1.20mmol),Na2CO3(0.21g,2.01mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=3:1)得到目标化合物(9a)(R)-4-氯-N-(1-(4-氟苯基)乙基)酞嗪-1-胺)(0.12g,产率:39.58%,LCMS m/z=302.2[M+1]+)。
步骤二:将化合物(9a)(0.05g,0.16mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(37.53mg,0.18mmol),碳酸钠(35.12mg,0.33mmol)和Pd(dppf)Cl2(10.24mg,0.014mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=3:1)得到目标化合物9(((R)-2-(4-((1-(4-氟苯基)乙基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚)(0.02g,产率:28.24%,LCMS m/z=428.2[M+1]+)。
实施例10:(S)-2-(4-((1-(4-氟苯基)乙基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(1c)(0.20g,1.00mmol),(S)-1-(4-氟苯基)乙烷-1-胺(0.16g,1.20mmol),Na2CO3(0.21g,2.01mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=3:1)得到目标化合物(10a)((S)-4-氯-N-(1-(4-氟苯基)乙基)酞嗪-1-胺)(0.12g,产率:39.58%,LCMS m/z=302.2[M+1]+)。
步骤二:将化合物(10a)(0.05g,0.16mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(37.53mg,0.18mmol),碳酸钠(35.12mg,0.33mmol)和Pd(dppf)Cl2(10.24mg,0.014mol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30m×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=3:1)得到目标化合物10(((S)-2-(4-((1-(4-氟苯基)乙基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚)(0.015g,产率:21.18%,LCMS m/z=428.2[M+1]+)。
实施例11:2-(4-(丁胺基)酞嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(1c)(0.10g,0.50mmol),正丁胺(0.036g,0.50mmol),Na2CO3(0.11g,1.00mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=3:1)得到目标化合物(11a)(正丁基-4-氯酞嗪-1-胺)(0.05g,产率:42.22%,LCMS m/z=236.2[M+1]+)。
步骤二:苯酚将化合物(11a)(0.05g,0.21mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(52.42mg,0.25mmol),碳酸钠(44.96mg,0.42mmol)和Pd(dppf)Cl2(10.24mg,0.014mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=3:1)得到目标化合物11((2-(4-(丁胺基)酞嗪-1-基)-5-(三氟甲基))(0.025g,产率:32.61%,LCMS m/z=362.2[M+1]+)。
实施例12:(R)-2-(4-((1-(吡啶-2-基)乙基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚
步骤一:将化合物(1c)(0.10g,0.50mmol),(R)-1-(吡啶-2-基)乙烷-1-胺(67.52mg,0.55mmol),Na2CO3(0.11g,1.00mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=3:1)得到目标化合物(12a)((R)-4-氯-N-(1-(吡啶-2-基)乙基)邻苯二甲嗪-1-胺)(0.06g,产率:41.94%,LCMS m/z=285.2[M+1]+)。
步骤二:将化合物(12a)(0.06g,0.21mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(52.07mg,0.25mmol),碳酸钠(44.67mg,0.42mmol)和Pd(dppf)Cl2(15.36mg,0.021mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=3:1)得到目标化合物12((R)-2-(4-((1-(吡啶-2-基)乙基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚)(0.025g,产率:28.91%,LCMS m/z=411.2[M+1]+)。
实施例13:(S)-2-(4-((1-(吡啶-2-基)乙基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(1c)(0.10g,0.50mmol),(S)-1-(吡啶-2-基)乙烷-1-胺(67.52mg,0.55mmol),Na2CO3(0.11g,1.00mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=3:1)得到目标化合物(13a)((S)-4-氯-N-(1-(吡啶-2-基)乙基)邻苯二甲嗪-1-胺)(0.05g,产率:34.95%,LCMS m/z=285.2[M+1]+)。
步骤二:将化合物(13a)(0.05g,0.17mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(43.39mg,0.21mmol),碳酸钠(38.22mg,0.35mmol)和Pd(dppf)Cl2(15.36mg,0.021mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=3:1)得到目标化合物13((S)-2-(4-((1-(吡啶-2-基)乙基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚)(0.02g,产率:27.75%,LCMS m/z=411.2[M+1]+)。
实施例14:2-(5-{[(3R)-1-甲基哌啶-3-基]氨基}吡啶并[2,3-d]哒嗪-8-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物呋喃[3,4-b]吡啶-5,7-二酮(14a)(3.0g,20.12mmol),N2H4.H2O(3.02g,60.36mmol)溶于醋酸(50mL)中,加热到120度回流过夜。TLC确定反应完全,将反应液直接浓缩干后加水(50ml)分散固体,过滤,滤饼抽干后真空干燥过夜,得到目标化合物(14b)(6,7-二氢吡啶并[2,3-d]哒嗪-5,8-二酮)(2.30g,产率:70.07%,LCMS m/z=164.2[M+1]+)。
步骤二:将化合物(14b)(2.30g,14.10mmol)溶于POCl3(20mL)中,加热到100度反应过夜。TLC确定反应完全,将反应液直接浓缩,除掉POCl3后,将油状物粗品慢慢滴加入冰水中(50ml),充分搅拌,用2N氢氧化钠水溶液调节PH=8,乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=10:1)得到目标化合物(14c)(5,8-二氯吡啶并[2,3-d]哒嗪)(1.25g,产率:44.33%,LCMS m/z=200.2[M+1]+)。
步骤三:将化合物(14c)(0.20g,1.00mmol),(R)-1-甲基哌啶-3-胺(0.14g,1.20mmol),Na2CO3(0.21g,1.99mmol)溶于干燥DMF(3mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物(14d)((3R)-N-(8-氯吡啶并[2,3-d]哒嗪-5-基)-1-甲基哌啶-3-胺)(0.13g,产率:46.80%,LCMS m/z=278.2[M+1]+)。
步骤四:将化合物(14d)(0.05g,0.18mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(44.00mg,0.22mmol),碳酸钠(29.15mg,0.27mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物14(2-(5-{[(3R)-1-甲基哌啶-3-基]氨基}吡啶并[2,3-d]哒嗪-8-基)-5-(三氟甲基)苯酚)(0.022g,产率:30.30%,LCMS m/z=404.4[M+1]+)。
实施例15:2-(8-{[(3R)-1-甲基哌啶-3-基]氨基}吡啶并[2,3-d]哒嗪-5-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(14c)(0.20g,1.00mmol),(R)-1-甲基哌啶-3-胺(0.14g,1.20mmol),Na2CO3(0.21g,1.99mmol)溶于干燥DMF(3mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(15d)((3R)-N-(5-氯吡啶并[2,3-d]哒嗪-8-基)-1-甲基哌啶-3-胺)(0.04g,产率:14.40%,LCMS m/z=278.2[M+1]+)。
步骤二:将化合物(15d)(0.04g,0.14mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(35.00mg,0.17mmol),碳酸钠(22.10mg,0.21mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物15(2-(8-{[(3R)-1-甲基哌啶-3-基]氨基}吡啶并[2,3-d]哒嗪-5-基)-5-(三氟甲基)苯酚)(0.015g,产率:26.56%,LCMS m/z=404.4[M+1]+)。
实施例16:2-(7-氟-4-{[(3R)-1-甲基哌啶-3-基]氨基}邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物5-氟异苯并呋喃-1,3-二酮(16a)(5.0g,30.10mmol),N2H4.H2O(7.53g,150.50mmol)溶于醋酸(50mL)中,加热到120度回流过夜。TLC确定反应完全,将反应液直接浓缩干后加水(50ml)分散固体,过滤,滤饼抽干后真空干燥过夜,得到目标化合物(16b)(6-氟-2,3-二氢邻苯二甲嗪-1,4-二酮)(5.40g,产率:99.59%,LCMS m/z=181.1[M+1]+)。
步骤二:将化合物(16b)(5.40g,29.98mmol)溶于POCl3(30mL)中,加热到100度反应过夜。TLC确定反应完全,将反应液直接浓缩,除掉POCl3后,将油状物粗品慢慢滴加入冰水中(50ml),充分搅拌,用2N氢氧化钠水溶液调节PH=8,乙酸乙酯萃取(50mL×3),合并有机相,饱和食盐水洗(50mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=5:1)得到目标化合物(16c)(1,4-二氯-6-氟邻苯二甲嗪)(4.83g,产率:74.23%,LCMS m/z=217.0[M+1]+)。
步骤三:将化合物(16c)(0.20g,0.92mmol),(R)-1-甲基哌啶-3-胺(0.14g,1.20mmol),Na2CO3(0.21g,1.99mmol)溶于干燥DMF(3mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物(16d)((R)-4-氯-6-氟-N-(1-甲基哌啶-3-基)邻苯二甲嗪-1-胺)(0.05g,产率:18.41%,LCMS m/z=295.2[M+1]+)。
步骤四:将化合物(16d)(0.05g,0.17mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(44.00mg,0.22mmol),碳酸钠(29.15mg,0.27mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物16((R)-2-(7-氟-4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚)(0.01g,产率:14.02%,LCMS m/z=421.4[M+1]+)。
实施例17:(R)-2-(1-((1-甲基哌啶-3-基)氨基)吡啶[3,4-d]哒嗪-4-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物呋喃[3,4-c]吡啶-1,3-二酮(17a)(3.0g,20.12mmol),N2H4.H2O(3.02g,60.36mmol)溶于醋酸(50mL)中,加热到120度回流过夜。TLC确定反应完全,将反应液直接浓缩干后加水(50ml)分散固体,过滤,滤饼抽干后真空干燥过夜,得到目标化合物(17b)(2,3-二氢吡啶并[3,4-d]哒嗪-1,4-二酮)(2.10g,产率:63.97%,LCMS m/z=164.2[M+1]+)。
步骤二:将化合物(17b)(2.10g,12.87mmol)溶于POCl3(20mL)中,加热到100度反应过夜。TLC确定反应完全,将反应液直接浓缩,除掉POCl3后,将油状物粗品慢慢滴加入冰水中(50ml),充分搅拌,用2N氢氧化钠水溶液调节PH=8,乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=10:1)得到目标化合物(17c)(1,4-二氯吡啶并[3,4-d]哒嗪)(0.92g,产率:32.63%,LCMS m/z=200.2[M+1]+)。
步骤三:将化合物(17c)(0.20g,1.00mmol),(R)-1-甲基哌啶-3-胺(0.14g,1.20mmol),Na2CO3(0.21g,1.99mmol)溶于干燥DMF(3mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物(17d)((R)-4-氯-N-(1-甲基哌啶-3-基)吡啶并[3,4-d]哒嗪-1-胺)(0.11g,产率:39.60%,LCMS m/z=278.2[M+1]+)。
步骤四:将化合物(17d)(0.05g,0.18mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(44.00mg,0.22mmol),碳酸钠(29.15mg,0.27mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物17((R)-2-(1-((1-甲基哌啶-3-基)氨基)吡啶[3,4-d]哒嗪-4-基)-5-(三氟甲基)苯酚)(0.01g,产率:13.77%,LCMS m/z=404.4[M+1]+)。
实施例18:2-(4-((反式)-4-(二甲氨基)环己基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(1c)(0.20g,1.00mmol),(反式)-N1,N1-二甲基环己烷-1,4-二胺(0.14g,1.00mmol),Na2CO3(0.21g,1.99mmol)溶于干燥DMF(3mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(18b)(反式)-N1-(4-氯邻苯二甲嗪-1-基)-N4,N4-二甲基环己烷-1,4-二胺(0.04g,产率:13.15%,LCMS m/z=305.2[M+1]+)。
步骤二:将化合物(18b)(0.04g,0.13mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(35.00mg,0.17mmol),碳酸钠(22.10mg,0.21mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物18 2-(4-((反式)-4-(二甲氨基)环己基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚(0.012g,产率:21.46%,LCMS m/z=431.5[M+1]+)。
实施例19:2-(4-((顺式)-4-(二甲氨基)环己基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(1c)(0.20g,1.00mmol),(顺式)-N1,N1-二甲基环己烷-1,4-二胺(0.14g,1.00mmol),Na2CO3(0.21g,1.99mmol)溶于干燥DMF(3mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(19b)(顺式)-N1-(4-氯邻苯二甲嗪-1-基)-N4,N4-二甲基环己烷-1,4-二胺(0.05g,产率:16.45%,LCMS m/z=305.2[M+1]+)。
步骤二:将化合物(19b)(0.05g,0.13mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(35.00mg,0.17mmol),碳酸钠(22.10mg,0.21mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物19 2-(4-((顺式)-4-(二甲氨基)环己基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚(0.020g,产率:35.78%,LCMS m/z=431.5[M+1]+)。
实施例20:2-(4-((2-羟基-2-甲基丙基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(1c)(0.20g,1.00mmol),1-氨基-2-甲基丙烷-2-醇(0.14g,1.00mmol),Na2CO3(0.21g,1.99mmol)溶于干燥DMF(3mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(20b)1-((4-氯酞嗪-1-基)氨基)-2-甲基丙烷-2-醇(0.05g,产率:19.92%,LCMS m/z=252.1[M+1]+)。
步骤二:将化合物(20b)(0.05g,0.20mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(50.00mg,0.24mmol),碳酸钠(42.40mg,0.40mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物20 2-(4-((2-羟基-2-甲基丙基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚(0.01g,产率:11.60%,LCMS m/z=378.4[M+1]+)。
实施例21:2-(4-((2-吗啉乙基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(1c)(0.20g,1.00mmol),2-吗啉醚-1-胺(0.12g,1.00mmol),Na2CO3(0.21g,1.99mmol)溶于干燥DMF(3mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(21b)4-氯-N-(2-吗啉乙基)邻苯二甲嗪-1-胺(0.05g,产率:17.12%,LCMS m/z=293.1[M+1]+)。
步骤二:将化合物(21b)(0.05g,0.17mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(42.00mg,0.20mmol),碳酸钠(42.40mg,0.40mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物21 2-(4-((2-吗啉乙基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚(0.01g,产率:11.60%,LCMS m/z=419.4[M+1]+)。
实施例22:(R)-2-(4-(哌啶-3-基氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(1c)(0.20g,1.00mmol),(R)-3-氨基哌啶-1-羧酸叔丁酯(0.20g,1.00mmol),Na2CO3(0.21g,1.99mmol)溶于干燥DMF(10mL)中,此混合体系置于50mL单口瓶中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(EA:PE=1:1)分别得到目标化合物(22a)(叔丁基(R)-3-((4-氯酞嗪-1-基)氨基)哌啶-1-羧酸酯)(0.22g,产率:60.34%,LCMS m/z=363.2[M+1]+)。
步骤二:将化合物(22a)(0.22g,0.61mmol)溶于二氯甲烷(10mL)中,加入三氟乙酸(2mL)中,室温反应过夜。TLC确定反应完全,将反应液直接浓缩,除掉三氟乙酸后,用2N氢氧化钠水溶液调节PH=8,乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,得到目标化合物(22b)((R)-4-氯-N-(哌啶-3-基)邻苯二甲嗪-1-胺)(0.11g,产率:69.05%,LCMS m/z=263.2[M+1]+)。
步骤三:将化合物(22b)(0.05g,0.19mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(44.00mg,0.22mmol),碳酸钠(29.15mg,0.27mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物22((R)-2-(4-(哌啶-3-基氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚)(0.03g,产率:40.59%,LCMS m/z=389.2[M+1]+)。
实施例23:(R)-2-(4-((1-乙基哌啶-3-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(22)(0.02g,0.051mmol),乙醛四氢呋喃溶液(0.20mL,5.0M),溶于干燥四氢呋喃(5mL)中,滴加两滴醋酸,此混合体系置于50mL单口瓶中室温搅拌1小时后,加入NaBH(OAc)3,继续反应3小时。TLC反应完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(23)((R)-2-(4-((1-乙基哌啶-3-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚)(0.01g,产率:46.63%,LCMS m/z=417.4[M+1]+)。
实施例24:(R)-2-(4-((1-甲基吡咯烷-3-基)氨基)酞嗪-1-基)-5-(三氟甲基)苯酚
步骤一:将化合物(1c)(0.20g,1.00mmol),(R)-1-甲基吡咯烷-3-胺(0.11g,1.1mmol),Na2CO3(0.21g,2.0mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(24a)((R)-4-氯-N-(1-甲基吡咯烷-3-基)酞嗪-1-胺)(0.06g,产率:21.6%,LCMS m/z=263.4[M+1]+)。
步骤二:室温下将化合物(24a)(27mg,0.10mmol),2-羟基-4-(三氟甲基)苯基)硼酸(0.045g,0.217mmol),(79mg,0.36mmol),碳酸钠(42mg,0.40mmol)和Pd(dppf)Cl2(5mg,0.007mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物24((R)-2-(4-((1-甲基吡咯烷-3-基)氨基)酞嗪-1-基)-5-(三氟甲基)苯酚)(30mg,产率:71.24%,LCMS m/z=389.4[M+1]+)
实施例25:(R)-2-(4-((1-乙基吡咯烷-3-基)氨基)酞嗪-1-基)-5-(三氟甲基)苯酚
步骤一:将化合物(1c)(0.20g,1.00mmol),(R)-1-乙基吡咯烷-3-胺(0.14g,1.1mmol),Na2CO3(0.21g,2.0mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(25a)((R)-4-氯-N-(1-乙基吡咯烷-3-基)酞嗪-1-胺)(0.10g,产率:36.23%,LCMS m/z=277.4[M+1]+)。
步骤二:室温下将化合物(24a)(28mg,0.10mmol),2-羟基-4-(三氟甲基)苯基)硼酸(0.045g,0.217mmol),(79mg,0.36mmol),碳酸钠(42mg,0.40mmol)和Pd(dppf)Cl2(5mg,0.007mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物25((R)-2-(4-((1-乙基吡咯烷-3-基)氨基)酞嗪-1-基)-5-(三氟甲基)苯酚)(20mg,产率:49.75%,LCMS m/z=403.4[M+1]+)
实施例27:(R)-2-(4-(((1-乙基吡咯烷-2-基)甲基)氨基)酞嗪-1-基)-5-(三氟甲基)苯酚
步骤一:将化合物(1c)(0.20g,1.00mmol),(R)-(1-乙基吡咯烷-2-基)甲胺(0.11g,1.1mmol),Na2CO3(0.21g,2.0mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(27a)((R)-4-氯-N-((1-乙基吡咯烷-2-基)甲基)酞嗪-1-胺)(0.08g,产率:27.5%,LCMS m/z=291.4[M+1]+)。
步骤二:室温下将化合物(27a)(30mg,0.10mmol),2-羟基-4-(三氟甲基)苯基)硼酸(0.045g,0.217mmol),(79mg,0.36mmol),碳酸钠(42mg,0.40mmol)和Pd(dppf)Cl2(5mg,0.007mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物27((R)-2-(4-(((1-乙基吡咯烷-2-基)甲基)氨基)酞嗪-1-基)-5-(三氟甲基)苯酚)(10mg,产率:23.98%,LCMS m/z=417.4[M+1]+)实施例29:(R)-2-(4-((6,7-二氢-5H-环戊烷[b]吡啶-5-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(1c)(0.20g,1.00mmol),(R)-6,7-二氢-5H-环戊烷[b]吡啶-5-胺(0.13g,1.00mmol),Na2CO3(0.21g,1.99mmol)溶于干燥DMF(3mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(29b)(R)-4-氯-N-(6,7-二氢-5H-环戊烷[b]吡啶-5-基)邻苯二甲嗪-1-胺(0.06g,产率:20.27%,LCMS m/z=297.8[M+1]+)。
步骤二:将化合物(29b)(0.06g,0.20mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(50.00mg,0.24mmol),碳酸钠(42.40mg,0.40mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物29(R)-2-(4-((6,7-二氢-5H-环戊烷[b]吡啶-5-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚(0.01g,产率:11.84%,LCMS m/z=423.5[M+1]+)。
实施例30:(S)-2-(4-((6,7-二氢-5H-环戊烷[b]吡啶-5-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(1c)(0.20g,1.00mmol),(S)-6,7-二氢-5H-环戊烷[b]吡啶-5-胺(0.13g,1.00mmol),Na2CO3(0.21g,1.99mmol)溶于干燥DMF(3mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(30b)(S)-4-氯-N-(6,7-二氢-5H-环戊烷[b]吡啶-5-基)邻苯二甲嗪-1-胺(0.05g,产率:16.83%,LCMS m/z=297.8[M+1]+)。
步骤二:将化合物(30b)(0.06g,0.17mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(42.00mg,0.20mmol),碳酸钠(42.40mg,0.40mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物30(R)-2-(4-((6,7-二氢-5H-环戊烷[b]吡啶-5-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚(0.01g,产率:13.94%,LCMS m/z=423.5[M+1]+)。
实施例31:(R)-2-(4-((1-甲基哌啶-3-基)氨基)酞嗪-1-基)苯酚
步骤一:室温下将化合物(1d)(50mg,0.18mmol),(2-羟基苯基)硼酸(50mg,0.36mmol),碳酸钠(60mg,0.57mmol)和Pd(dppf)Cl2(5mg,0.007mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物31((R)-2-(4-((1-甲基哌啶-3-基)氨基)酞嗪-1-基)苯酚)(20mg,产率:33.23%,LCMS m/z=335.4[M+1]+)
实施例32:(R)-2-(4-((1-乙基哌啶-3-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(22b)(0.01g,0.038mmol),三乙胺(77.03mg,0.76mmol),溶于二氯甲烷(5mL)中,滴加乙酰氯(29.88mg,0.038mmol),室温反应0.5小时。TLC反应完全,向反应液加入到水中(20ml),充分搅拌,DCM萃取(20mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(EA:PE=1:3)得到目标化合物(32a)((R)-1-(3-((4-氯酞嗪-1-基)氨基)哌啶-1-基)乙烷-1-酮)(0.06g,产率:51.72%,LCMS m/z=305.2[M+1]+)。
步骤二:将化合物(32a)(0.05g,0.16mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(44.00mg,0.22mmol),碳酸钠(29.15mg,0.27mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物32((R)-1-(3-((4-(2-羟基-4-(三氟甲基)苯基)邻苯二甲嗪-1-基)氨基)哌啶-1-基)乙烷-1-酮)(0.02g,产率:28.32%,LCMS m/z=431.2[M+1]+)。
实施例33:2-(4-((-3-羟基环己基)氨基)酞嗪-1-基)-5-(三氟甲基)苯酚的异构体1和异构体2的合成
步骤一:将化合物(1c)(0.28g,1.39mmol),3-氨基环己醇(0.16g,1.39mmol),Na2CO3(0.44g,4.17mmol)溶于干燥DMAc(2.5mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(33a)3-((4-氯酞嗪-1-基)氨基)环己-1-醇(0.35g,产率:90.66%,LCMS m/z=278.2[M+1]+)。
步骤二:将化合物(33a)(0.05g,0.18mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(0.048g,0.23mmol),碳酸钠(0.057g,0.54mmol)和Pd(dppf)Cl2(15.00mg,0.02mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=20:1)得到化合物(2-(4-((-3-羟基环己基)氨基)酞嗪-1-基)-5-(三氟甲基)苯酚)的异构体1(化合物33)(展开剂DCM:CH3OH=10:1,Rf=0.2,15mg,产率:20.66%,LC-MS m/z=404.5[M+1]+)和异构体2(化合物34)(展开剂DCM:CH3OH=10:1,Rf=0.3,15mg,产率:20.66%,LCMS m/z=404.2[M+1]+)。
实施例35:2-(4-((1-甲基哌啶-4-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(1c)(0.20g,1.00mmol),1-甲基哌啶-4-胺(0.12g,1.00mmol),Na2CO3(0.21g,1.99mmol)溶于干燥DMF(3mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(35b)4-氯-N-(1-甲基哌啶-4-基)邻苯二甲嗪-1-胺(0.06g,产率:21.73%,LCMS m/z=277.2[M+1]+)。
步骤二:将化合物(35b)(0.03g,0.21mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(25.00mg,0.24mmol),碳酸钠(21.20mg,0.20mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物35 2-(4-((1-甲基哌啶-4-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚(0.02g,产率:23.69%,LCMS m/z=403.4[M+1]+)。
实施例36:(R)-2-(1-甲基-7-((1-甲基哌啶-3-基)氨基)-1H-咪唑[4,5-d]哒嗪-4-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物1H-咪唑-4,5-二羧酸二甲酯(36a)(3.0g,16.29mmol),碘甲烷(3.47g,24.43mmol),碳酸钾(3.38g,24.43mmol)溶于DMF(20mL)中,加热到60度反应3小时。TLC确定反应完全,将反应液加入水中(50ml),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物(36b)(1-甲基-1H-咪唑-4,5-二甲酸二甲酯)(0.80g,产率:24.78%,LCMS m/z=199.2[M+1]+)。
步骤二:将化合物1-甲基-1H-咪唑-4,5-二甲酸二甲酯(36b)(0.8g,4.04mmol),N2H4.H2O(0.61g,12.12mmol)溶于醋酸(5mL)中,加热到120度回流过夜。TLC确定反应完全,将反应液直接浓缩干后加水(30ml)分散固体,过滤,滤饼抽干后真空干燥过夜,得到目标化合物(36c)(1-甲基-5,6-二氢-1H-咪唑并[4,5-d]哒嗪-4,7-二酮)(0.40g,产率:59.59%,LCMS m/z=167.2[M+1]+)。
步骤三:将化合物(36c)(0.40g,2.41mmol)溶于POCl3(10mL)中,加热到100度反应过夜。TLC确定反应完全,将反应液直接浓缩,除掉POCl3后,将油状物粗品慢慢滴加入冰水中(50ml),充分搅拌,用2N氢氧化钠水溶液调节PH=8,乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=5:1)得到目标化合物(36d)(4,7-二氯-1-甲基-1H-咪唑并[4,5-d]哒嗪)(0.40g,产率:81.75%,LCMS m/z=203.2[M+1]+)。
步骤四:将化合物(36d)(0.40g,1.97mmol),(R)-1-甲基哌啶-3-胺(0.27g,2.36mmol),Na2CO3(0.21g,1.97mmol)溶于干燥DMF(5mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物(36e)((R)-4-氯-1-甲基-N-(1-甲基哌啶-3-基)-1H-咪唑并[4,5-d]哒嗪-7-胺)(0.05g,产率:9.04%,LCMS m/z=281.2[M+1]+)。
步骤五:将化合物(36e)(0.04g,0.14mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(35.00mg,0.17mmol),碳酸钠(22.10mg,0.22mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物36((R)-2-(1-甲基-7-((1-甲基哌啶-3-基)氨基)-1H-咪唑[4,5-d]哒嗪-4-基)-5-(三氟甲基)苯酚)(0.020g,产率:35.15%,LCMS m/z=407.4[M+1]+)。
实施例37:(R)-2-(1-甲基-4-((1-甲基哌啶-3-基)氨基)-1H-咪唑[4,5-d]哒嗪-7-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(36d)(0.40g,1.97mmol),(R)-1-甲基哌啶-3-胺(0.27g,2.36mmol),Na2CO3(0.21g,1.97mmol)溶于干燥DMF(5mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物(37a)((R)-7-氯-1-甲基-N-(1-甲基哌啶-3-基)-1H-咪唑并[4,5-d]哒嗪-4-胺)(0.10g,产率:18.08%,LCMS m/z=281.2[M+1]+)。
步骤二:将化合物(37a)(0.05g,0.18mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(44.00mg,0.22mmol),碳酸钠(22.10mg,0.22mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物37((R)-2-(1-甲基-4-((1-甲基哌啶-3-基)氨基)-1H-咪唑[4,5-d]哒嗪-7-基)-5-(三氟甲基)苯酚)(0.030g,产率:41.04%,LCMS m/z=407.4[M+1]+)。
实施例38:(R)-2-(4-((1-甲基哌啶-3-基)氨基)-7-(三氟甲基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物4-(三氟甲基)邻苯二甲酸(38a)(2.0g,8.54mmol)溶于15ml二氯亚砜中,滴加2滴干燥DMF,加热到回流反应2小时,将此反应液浓缩干用甲苯(20mL)重复溶解后浓缩干,残留物溶于醋酸(30mL)中,加入N2H4.H2O(1.85g,37.00mmol)加热到120℃回流过夜。将反应液直接浓缩干后加水(20ml)分散固体,过滤,滤饼抽干后真空干燥过夜,得到目标化合物38b(6-(三氟甲基)-2,3-二氢邻苯二甲嗪-1,4-二酮)(0.70g,产率:35.61%,LCMS m/z=231.2[M+1]+)。
步骤二:将化合物(38b)(0.70g,3.04mmol)溶于POCl3(10mL)中,加热到100℃反应过夜。TLC确定反应完全,将反应液直接浓缩,除掉POCl3后,将油状物粗品慢慢滴加入冰水中(50ml),充分搅拌,用2N氢氧化钠水溶液调节PH=8,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=10:1)得到目标化合物(38c)(1,4-二氯-6-(三氟甲基)邻苯二甲嗪)(0.52g,产率:64.02%,LCMS m/z=267.2[M+1]+)。
步骤三:将化合物(38c)(0.22g,0.82mmol),(R)-1-甲基哌啶-3-胺(0.12g,1.04mmol),Na2CO3(0.20g,1.89mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(38d)与(39d)的混合物(0.15g,产率:52.81%,LCMS m/z=345.2[M+1]+)。
步骤四:将化合物(38d)与(39d)混合物(0.10g,0.29mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(0.074g,0.357mmol),碳酸钠(0.058g,0.55mmol)和Pd(dppf)Cl2(20.00mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物PTLC分离(DCM:CH3OH=10:1)得到目标化合物38((R)-2-(4-((1-甲基哌啶-3-基)氨基)-7-(三氟甲基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚)(0.01g,产率:7.33%,LCMS m/z=471.4[M+1]+)。
实施例39:(R)-2-(4-((1-甲基哌啶-3-基)氨基)-6-(三氟甲基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚的合成
步骤一:将化合物(38c)(0.22g,0.82mmol),(R)-1-甲基哌啶-3-胺(0.12g,1.04mmol),Na2CO3(0.20g,1.89mmol)溶于干燥DMF(2mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(38d)与(39d)的混合物(0.15g,产率:52.81%,LCMS m/z=345.2[M+1]+)。
步骤二:将化合物(38d)与(39d)混合物(0.10g,0.29mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(0.074g,0.357mmol),碳酸钠(0.058g,0.55mmol)和Pd(dppf)Cl2(20.00mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物PTLC分离(DCM:CH3OH=10:1)得到目标化合物39(R)-2-(4-((1-甲基哌啶-3-基)氨基)-6-(三氟甲基)邻苯二甲嗪-1-基)-5-(三氟甲基)苯酚)(0.007g,产率:5.13%,LCMS m/z=471.4[M+1]+)。
实施例40:(R)-5-甲基-2-(4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)苯酚的合成
步骤:将化合物(1d)(0.05g,0.18mmol),(2-羟基-4-甲基苯基)硼酸(40.77mg,0.27mmol),碳酸钠(42.40mg,0.40mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物40(R)-5-甲基-2-(4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)苯酚(0.02g,产率:23.69%,LCMS m/z=349.2[M+1]+)。
实施例41:(R)-2-(4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲氧基)苯酚的合成
步骤:将化合物(1d)(0.05g,0.18mmol),(2-羟基-4-(三氟甲氧基)苯基)硼酸(59.94mg,0.27mmol),碳酸钠(42.40mg,0.40mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物41(R)-2-(4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)-5-(三氟甲氧基)苯酚(0.02g,产率:26.52%,LCMS m/z=419.2[M+1]+)。
实施例43:(R)-(1-(2-羟基-4-(三氟甲基)苯基)-4-((1-甲基哌啶-3-基)氨基)酞嗪-6-基)二甲基氧化膦
步骤一:将化合物(43a)(1.0g,4.44mmol),N2H4·H2O(2.5g,41.1mmol,80%wt)溶于醋酸(20mL)中,加热到120℃回流过夜。TLC确定反应完全,将反应液直接过滤,水洗(20mL×3),滤饼抽干后真空干燥,,得到目标化合物43b(6-溴代萘嗪-1,4-二醇)(1.0g,产率:94.34%,LCMS m/z=241.1[M+1]+)。
步骤二:将化合物(43b)(0.70g,2.9mmol)溶于POCl3(4mL)中,加热到110℃反应过夜。TLC确定反应完全,将反应液体积浓缩至十分之一后慢慢滴加入冰水中(20ml),充分搅拌,用2N氢氧化钠水溶液调节PH=8,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=20:1)得到目标化合物43c(6-溴-1,4-二氯酞嗪)(0.61g,产率:75.68%,LCMS m/z=277.0[M+1]+)。
步骤三:将化合物(43c)(0.60g,2.16mmol),(R)-1-甲基哌啶-3-胺(0.25g,2.16mmol),Na2CO3(0.43g,4.00mmol)溶于干燥DMF(4mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物(43d)((R)-7-溴-4-氯-N-(1-甲基哌啶-3-基)酞嗪-1-胺)(0.50g,产率:65.09%,LCMS m/z=355.1[M+1]+)。
步骤四:室温下将化合物(43d)(0.40g,1.12mmol),二甲基氧化膦(87.4mg,1.12mmol),醋酸钯(25mg,0.11mmol),Xantphos(92mg,0.16mmol),无水磷酸钾(467mg,2.2mmol)加入到干燥的DMF(6mL)中,氩气置换3次,加热到150℃反应3小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物43e((R)-(1-氯-4-((1-甲基哌嗪-3-基)氨基)酞嗪-6-基)二甲基氧化膦)(32mg,产率:7.7%,LCMS m/z=353.2[M+1]+)和化合物43f(R)-4-氯-1-((1-甲基哌嗪-3-基)氨基)酞嗪-6-基)二甲基氧化膦)(30mg,产率:7.6%,LCMS m/z=353.2[M+1]+)。
步骤五:将化合物(43e)(30mg,0.08mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(35mg,0.17mmol),碳酸钠(26mg g,0.24mmol)和Pd(dppf)Cl2(5mg,0.007mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物43((R)-(1-(2-羟基-4-(三氟甲基)苯基)-4-((1-甲基哌啶-3-基)氨基)酞嗪-6-基)二甲基氧化膦)(0.01g,产率:24.59%,LCMS m/z=479.6[M+1]+)。
实施例44:(R)-5-氟-2-(4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)苯酚的合成
步骤:将化合物(1d)(0.05g,0.18mmol),(4-氟-2-羟基苯基)硼酸(41.85mg,0.27mmol),碳酸钠(42.40mg,0.40mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物44(R)-5-氟-2-(4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)苯酚(0.02g,产率:31.54%,LCMS m/z=353.2[M+1]+)。
实施例45:(R)-(4-(2-羟基-4-(三氟甲基)苯基)-1-((1-甲基哌啶-3-基)氨基)酞嗪-6-基)二甲基氧化膦
步骤一:将化合物(43f)(30mg,0.08mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(35mg,0.17mmol),碳酸钠(26mg,0.24mmol)和Pd(dppf)Cl2(5mg,0.007mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物45(R)-(4-(2-羟基-4-(三氟甲基)苯基)-1-((1-甲基哌啶-3-基)氨基)酞嗪-6-基)二甲基氧化膦(0.01g,产率:24.59%,LCMSm/z=479.6[M+1]+)。
实施例46:(R)-4-氟-2-(4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)苯酚的合成
步骤:将化合物(1d)(0.05g,0.18mmol),(5-氟-2-羟基苯基)硼酸(41.85mg,0.27mmol),碳酸钠(42.40mg,0.40mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物46(R)-4-氟-2-(4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)苯酚(0.012g,产率:18.93%,LCMS m/z=353.2[M+1]+)。
实施例47:((R)-4-甲基-2-(4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)苯酚的合成
步骤:将化合物(1d)(0.05g,0.18mmol),(2-羟基-5-甲基苯基)硼酸(40.77mg,0.27mmol),碳酸钠(42.40mg,0.40mmol)和Pd(dppf)Cl2(19.75mg,0.027mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物47(R)-4-甲基-2-(4-((1-甲基哌啶-3-基)氨基)邻苯二甲嗪-1-基)苯酚(0.015g,产率:23.%,LCMS m/z=349.2[M+1]+)。
实施例48:2-(3-甲基-8-{[(3R)-1-甲基哌啶-3-基]氨基}吡啶并[2,3-d]哒嗪-5-基)-5-(三氟甲基)苯酚和
实施例49:2-(3-甲基-5-{[(3R)-1-甲基哌啶-3-基]氨基}吡啶并[2,3-d]哒嗪-8-基)-5-(三氟甲基)苯酚
步骤一:将化合物(48a)(3-甲基-5H,7H-呋喃并[3,4-b]吡啶-5,7-二酮)(1.0g,6.13mmol),N2H4·H2O(2.5g,41.1mmol,80%wt)溶于醋酸(20mL)中,加热到110℃回流过夜。TLC确定反应完全,将反应液直接过滤,水洗(20mL×3),滤饼抽干后真空干燥,,得到目标化合物43b(3-甲基吡啶并[2,3-d]哒嗪-5,8-二醇)(1.0g,产率:92.08%,LCMS m/z=177.1[M+1]+)。
步骤二:将化合物(48b)(1.0g,5.6mmol)溶于POCl3(5mL)中,加热到110℃反应过夜。TLC确定反应完全,将反应液体积浓缩至十分之一后慢慢滴加入冰水中(20ml),充分搅拌,用2N氢氧化钠水溶液调节PH=8,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=20:1)得到目标化合物48c(5,8-二氯-3-甲基吡啶并[2,3-d]哒嗪)(0.70g,产率:58.66%,LCMSm/z=214.2[M+1]+)。
步骤三:将化合物(48c)(0.46g,2.16mmol),(R)-1-甲基哌啶-3-胺(0.25g,2.16mmol),Na2CO3(0.43g,4.00mmol)溶于干燥DMF(4mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物48d((R)-5-氯-3-甲基-N-(1-甲基哌啶-3-基)吡啶并[2,3-d]哒嗪-8-胺)(0.20g,产率:31.73%,LCMS m/z=292.2[M+1]+)和化合物48e(3R)-N-(8-氯-3-甲基吡啶并[2,3-d]哒嗪-5-基)-1-甲基哌啶-3-胺(50mg,产率:7.95%,LCMS m/z=292.2[M+1]+)。
步骤四:将化合物(48d)(200mg,0.69mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(280mg,1.38mmol),碳酸钠(220mg,2.07mmol)和Pd(dppf)Cl2(50mg,0.07mmol)加入到10mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物48(2-(3-甲基-8-{[(3R)-1-甲基哌啶-3-基]氨基}吡啶并[2,3-d]哒嗪-5-基)-5-(三氟甲基)苯酚)(0.10g,产率:34.72%,LCMS m/z=418.6[M+1]+)。
步骤五:将化合物(48e)(25mg,0.086mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(35mg,0.17mmol),碳酸钠(28mg,0.26mmol)和Pd(dppf)Cl2(5mg,0.007mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物49(2-(3-甲基-5-{[(3R)-1-甲基哌啶-3-基]氨基}吡啶并[2,3-d]哒嗪-8-基)-5-(三氟甲基)苯酚)(20mg,产率:55.71%,LCMSm/z=418.6[M+1]+)。
实施例50:(R)-2-(3-乙基-8-((1-甲基哌啶-3-基)氨基)吡啶[2,3-d]哒嗪-5-基)-5-(三氟甲基)苯酚和
实施例51:(R)-2-(3-乙基-5-((1-甲基哌啶-3-基)氨基)吡啶[2,3-d]哒嗪-8-基)-5-(三氟甲基)苯酚
步骤一:将化合物(50a)3-乙基糠醛[3,4-b]吡啶-5,7-二酮(1.0g,5.64mmol),N2H4·H2O(2.5g,41.1mmol,80%wt)溶于醋酸(20mL)中,加热到110℃回流过夜。TLC确定反应完全,将反应液直接过滤,水洗(20mL×3),滤饼抽干后真空干燥,,得到目标化合物50b(3-乙基吡啶[2,3-d]哒嗪-5,8-二醇)(0.8g,产率:74.26%,LCMS m/z=192.2[M+1]+)。
步骤二:将化合物(50b)(0.8g,4.2mmol)溶于POCl3(5mL)中,加热到110℃反应过夜。TLC确定反应完全,将反应液体积浓缩至十分之一后慢慢滴加入冰水中(20ml),充分搅拌,用2N氢氧化钠水溶液调节PH=8,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=20:1)得到目标化合物50c(5,8-二氯-3-乙基吡啶并[2,3-d]哒嗪)(0.70g,产率:73.09%,LCMSm/z=228.1[M+1]+)。
步骤三:将化合物(50c)(0.46g,2.01mmol),(R)-1-甲基哌啶-3-胺(0.25g,2.16mmol),Na2CO3(0.43g,4.00mmol)溶于干燥DMF(4mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物50d((R)-5-氯-3-乙基-N-(1-甲基哌啶-3-基)吡啶并[2,3-d]哒嗪-8-胺)(0.20g,产率:32.51%,LCMS m/z=306.2[M+1]+)和化合物50e(R)-8-氯-3-乙基-N-(1-甲基哌啶-3-基)吡啶并[2,3-d]哒嗪-5-胺(100mg,产率:16.25%,LCMS m/z=305.4[M+1]+)。
步骤四:将化合物(50d)(100mg,0.326mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(280mg,1.38mmol),碳酸钠(220mg,2.07mmol)和Pd(dppf)Cl2(50mg,0.07mmol)加入到10mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物50((R)-2-(3-乙基-8-((1-甲基哌啶-3-基)氨基)吡啶[2,3-d]哒嗪-5-基)-5-(三氟甲基)苯酚)(0.05g,产率:35.56%,LCMSm/z=432.6[M+1]+)。
步骤五:将化合物(50e)(100mg,0.326mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(35mg,0.17mmol),碳酸钠(28mg,0.26mmol)和Pd(dppf)Cl2(5mg,0.007mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物51((R)-2-(3-乙基-5-((1-甲基哌啶-3-基)氨基)吡啶[2,3-d]哒嗪-8-基)-5-(三氟甲基)苯酚)(0.1g,产率:71.17%,LCMS m/z=432.6[M+1]+)。
实施例52:(R)-2-(2-甲基-8-((1-甲基哌啶-3-基)氨基)吡啶[2,3-d]哒嗪-5-基)-5-(三氟甲基)苯酚和
实施例53:(R)-2-(2-甲基-5-((1-甲基哌啶-3-基)氨基)吡啶[2,3-d]哒嗪-8-基)-5-(三氟甲基)苯酚
步骤一:将化合物(52a)(2-甲基糠醛[3,4-b]吡啶-5,7-二酮)(1.0g,6.13mmol),N2H4·H2O(2.5g,41.1mmol,80%wt)溶于醋酸(20mL)中,加热到110℃回流过夜。TLC确定反应完全,将反应液直接过滤,水洗(20mL×3),滤饼抽干后真空干燥,,得到目标化合物52b(2-甲基吡啶[2,3-d]哒嗪-5,8-二醇)(1.0g,产率:92.08%,LCMS m/z=177.1[M+1]+)。
步骤二:将化合物(52b)(1.0g,5.6mmol)溶于POCl3(5mL)中,加热到110℃反应过夜。TLC确定反应完全,将反应液体积浓缩至十分之一后慢慢滴加入冰水中(20ml),充分搅拌,用2N氢氧化钠水溶液调节PH=8,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=20:1)得到目标化合物52c(5,8-二氯-2-甲基吡啶并[2,3-d]哒嗪)(0.70g,产率:58.66%,LCMSm/z=214.2[M+1]+)。
步骤三:将化合物(52c)(0.46g,2.16mmol),(R)-1-甲基哌啶-3-胺(0.25g,2.16mmol),Na2CO3(0.43g,4.00mmol)溶于干燥DMF(4mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物52d((R)-5-氯-2-甲基-N-(1-甲基哌啶-3-基)吡啶并[2,3-d]哒嗪-8-胺)(0.10g,产率:15.90%,LCMS m/z=292.4[M+1]+)和化合物52e((R)-8-氯-2-甲基-N-(1-甲基哌啶-3-基)吡啶并[2,3-d]哒嗪-5-胺)(0.10g,产率:15.90%,LCMS m/z=292.4[M+1]+)。
步骤四:将化合物(52d)(100mg,0.34mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(280mg,1.38mmol),碳酸钠(220mg,2.07mmol)和Pd(dppf)Cl2(50mg,0.07mmol)加入到10mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物52((R)-2-(2-甲基-8-((1-甲基哌啶-3-基)氨基)吡啶[2,3-d]哒嗪-5-基)-5-(三氟甲基)苯酚)(25mg,产率:17.63%,LCMSm/z=418.6[M+1]+)。
步骤五:将化合物(52e)(100mg,0.34mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(35mg,0.17mmol),碳酸钠(28mg,0.26mmol)和Pd(dppf)Cl2(5mg,0.007mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物53((R)-2-(2-甲基-5-((1-甲基哌啶-3-基)氨基)吡啶[2,3-d]哒嗪-8-基)-5-(三氟甲基)苯酚)(20mg,产率:14.10%,LCMS m/z=418.6[M+1]+)。
实施例54:(R)-2-(4-((1-甲基哌啶-3-基)氨基)噻吩并[3,4-d]哒嗪-1-基)-5-(三氟甲基)苯酚
步骤一:将化合物(54a)(3,4-噻吩二羧酸酐)(180mg,1.16mmol),N2H4·H2O(0.6mL,9.88mmol,80%wt)溶于醋酸(10mL)中,加热到110℃回流过夜。TLC确定反应完全,将反应液直接过滤,水洗(10mL×3),滤饼抽干后真空干燥,,得到目标化合物54b(噻吩并[3,4-d]哒嗪-1,4-二醇)(150mg,产率:76.89%,LCMS m/z=169.1[M+1]+)。
步骤二:将化合物(54b)(150mg,0.89mmol)溶于POCl3(3mL)中,加热到110℃反应过夜。TLC确定反应完全,将反应液体积浓缩至十分之一后慢慢滴加入冰水中(10ml),充分搅拌,用2N氢氧化钠水溶液调节pH=8,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=20:1)得到目标化合物54c(1,4-二氯噻吩并[3,4-d]哒嗪)(76mg,产率:41.64%,LCMS m/z=205.0[M+1]+)。
步骤三:将化合物(54c)(70mg,0.34mmol),(R)-1-甲基哌啶-3-胺(40mg,0.35mmol),Na2CO3(74mg,0.70mmol)溶于干燥DMF(3mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(10ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物54d((R)-4-氯-N-(1-甲基吡啶-3-基)噻吩并[3,4-d]哒嗪-1-胺)(50mg,产率:52.00%,LCMS m/z=283.1[M+1]+)。
步骤四:将化合物(54d)(50mg,0.18mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(74mg,0.36mmol),碳酸钠(60mg,0.57mmol)和Pd(dppf)Cl2(5mg,0.007mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物54((R)-2-(4-((1-甲基哌啶-3-基)氨基)噻吩并[3,4-d]哒嗪-1-基)-5-(三氟甲基)苯酚)(20mg,产率:27.2%,LCMS m/z=409.4[M+1]+)。
实施例55:(R)-5-氟-2-(3-甲基-8-((1-甲基哌啶-3-基)氨基)吡啶并[2,3-d]哒嗪-5-基)苯酚
步骤一:室温下将化合物(48d)(30mg,0.10mmol),5-氟-2-(四甲基-1,3,2-二氧杂硼-2-基)苯酚(86mg,0.36mmol),碳酸钠(42mg,0.40mmol)和Pd(dppf)Cl2(5mg,0.007mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物55((R)-5-氟-2-(3-甲基-8-((1-甲基哌啶-3-基)氨基)吡啶并[2,3-d]哒嗪-5-基)苯酚)(20mg,产率:45.36%,LCMS m/z=368.6[M+1]+)
实施例56:(R)-2-(3-甲基-8-((1-甲基哌啶-3-基)氨基)吡啶并[2,3-d]哒嗪-5-基)苯酚
步骤一:室温下将化合物(48d)(30mg,0.10mmol),5-氟-2-(四甲基-1,3,2-二氧杂硼-2-基)苯酚(79mg,0.36mmol),碳酸钠(42mg,0.40mmol)和Pd(dppf)Cl2(5mg,0.007mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物56((R)-2-(3-甲基-8-((1-甲基哌啶-3-基)氨基)吡啶并[2,3-d]哒嗪-5-基)苯酚)(30mg,产率:71.55%,LCMS m/z=350.6[M+1]+)
实施例60:5-甲基-2-(3-甲基-8-{[(3R)-1-甲基哌啶-3-基]氨基}吡啶并[2,3-d]哒嗪-5-基)苯酚
步骤一:室温下将化合物(48d)(30mg,0.10mmol),5-甲基-2-(四甲基-1,3,2-二氧杂硼-2-基)苯酚(47mg,0.20mmol),碳酸钠(42mg,0.40mmol)和Pd(dppf)Cl2(5mg,0.007mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物60(5-甲基-2-(3-甲基-8-{[(3R)-1-甲基哌啶-3-基]氨基}吡啶并[2,3-d]哒嗪-5-基)苯酚)(10mg,产率:27.51%,LCMS m/z=364.6[M+1]+)
实施例61:2-(3-甲基-8-{[(3R)-1-甲基哌啶-3-基]氨基}吡啶并[2,3-d]哒嗪-5-基)-5-(三氟甲氧基)苯酚
步骤一:室温下将化合物(48d)(30mg,0.10mmol),5-三氟甲氧基-2-(四甲基-1,3,2-二氧杂硼-2-基)苯酚(61mg,0.20mmol),碳酸钠(42mg,0.40mmol)和Pd(dppf)Cl2(5mg,0.007mmol)加入到5mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应16小时。旋干反应液后直接硅胶柱层析分离(DCM:CH3OH=10:1)得到化合物61(2-(3-甲基-8-{[(3R)-1-甲基哌啶-3-基]氨基}吡啶并[2,3-d]哒嗪-5-基)-5-(三氟甲氧基)苯酚)(20mg,产率:46.14%,LCMS m/z=434.6[M+1]+)
实施例62:((R)-2-(1-甲基-7-((1-甲基哌啶-3-基)氨基)-1H-吡唑[3,4-d]哒嗪-4-基)-5-(三氟甲基)苯酚)和
实施例63:((R)-2-(1-甲基-4-((1-甲基哌啶-3-基)氨基)-1H-吡唑[3,4-d]哒嗪-7-基)-5-(三氟甲基)苯酚)
步骤一:冰水浴下将化合物(62a)(10.0g,69.84mmol),DMAP(0.14g,1.25mmol),三乙胺(9.19g,90.79mmol)溶于干燥四氢呋喃中(100mL),向此混合液中慢慢滴加2-氯-2-氧乙酸乙酯(11.44g,83.81mmol)的四氢呋喃溶液(50mL),加完后自然升到室温反应1小时。TLC显示原料(62a)消耗完毕,过滤反应液中生成的盐,滤液重新加入到反应瓶中,加入1-甲基肼-1-羧酸叔丁酯(12.25g,83.81mmol),加完后继续室温下反应2小时。反应液直接浓缩干得到黄色固体,此固体用甲醇/水(100mL,v/v=1:1)重结晶,再真空干燥得到目标化合物62b((Z/E混合)-2-(2-(叔丁氧羰基)-2-甲基肼基)亚甲基)-3-氧代琥珀酸二乙酯)(19.2g,产率:79.83%)
步骤二:将原料(62b)(19.2g,55.75mmol)用乙酸乙酯(60ml)分散,加入HCl/二氧六环溶液(200ml),此混合溶液加热到50度反应3小时。浓缩干,重新用乙酸乙酯(200ml)溶解,用2N碳酸钠水溶液调节PH>7,分液,有机相用饱和食盐水洗(50mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=5:1)得到目标化合物62c(1-甲基-1H-吡唑-4,5-二羧酸二乙酯)(10.2g,产率:80.87%,LCMS m/z=227.2[M+1]+)
步骤三:将化合物1-甲基-1H-吡唑-4,5-二甲酸二甲酯(62c)(0.8g,4.04mmol),N2H4.H2O(0.61g,12.12mmol)溶于醋酸(5mL)中,加热到120度回流过夜。TLC确定反应完全,将反应液直接浓缩干后加水(30ml)分散固体,过滤,滤饼抽干后真空干燥过夜,得到目标化合物62d(1-甲基-1H-吡唑并[3,4-d]哒嗪-4,7-二醇)(0.40g,产率:59.59%,LCMS m/z=167.2[M+1]+)。
步骤四:将化合物62d(0.40g,2.41mmol)溶于POCl3(10mL)中,加热到100度反应过夜。TLC确定反应完全,将反应液直接浓缩,除掉POCl3后,将油状物粗品慢慢滴加入冰水中(50ml),充分搅拌,用2N氢氧化钠水溶液调节PH=8,乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(PE:EA=5:1)得到目标化合物(62e)(4,7-二氯-1-甲基-1H-吡唑并[3,4-d]哒嗪)(0.40g,产率:81.75%,LCMS m/z=203.2[M+1]+)。
步骤五:将化合物(62e)(0.40g,1.97mmol),(R)-1-甲基哌啶-3-胺(0.27g,2.36mmol),Na2CO3(0.21g,1.97mmol)溶于干燥DMF(5mL)中,此混合体系置于封管中加热到120度反应过夜。TLC确定原料转化完全,将反应液加入到水中(20ml),充分搅拌,乙酸乙酯萃取(10mL×3),合并有机相,饱和食盐水洗(10mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)分别得到目标化合物(62f与63f混合物)(((R)-4-氯-1-甲基-N-(1-甲基哌啶-3-基)-1H-吡唑并[3,4-d]哒嗪-7-胺,(R)-7-氯-1-甲基-N-(1-甲基哌啶-3-基)-1H-吡唑并[3,4-d]哒嗪-4-胺)(0.31g,产率:56.04%,LCMS m/z=281.2[M+1]+)。
步骤六:将化合物(62f与63f混合物)(0.31g,1.10mmol),(2-羟基-4-(三氟甲基)苯基)硼酸(350.00mg,1.72mmol),碳酸钠(220.10mg,2.22mmol)和Pd(dppf)Cl2(90.75mg,0.13mmol)加入到30mL二氧六环和水(v/v=4:1)混合溶剂中,氮气置换3次,加热到110℃反应3小时。反应液加水淬灭(50mL),乙酸乙酯萃取(30mL×3),合并有机相,饱和食盐水洗(30mL×3),无水硫酸钠干燥,过滤,滤液减压除去溶剂,残留物柱层析分离(DCM:CH3OH=10:1)得到目标化合物混合物(62与63混合物),再用pre-HPLC制备分离得到目标化合物62((R)-2-(1-甲基-7-((1-甲基哌啶-3-基)氨基)-1H-吡唑[3,4-d]哒嗪-4-基)-5-(三氟甲基)苯酚)(0.04g,产率:8.91%,LCMS m/z=407.4[M+1]+),目标化合物63((R)-2-(1-甲基-4-((1-甲基哌啶-3-基)氨基)-1H-吡唑[3,4-d]哒嗪-7-基)-5-(三氟甲基)苯酚)(0.16g,产率:35.66%,LCMS m/z=407.4[M+1]+)。
实施例26,28与实施例25类似,将步骤一中的胺用市售的对应原料胺替换。
实施例57-59与实施例36类似,将步骤二中的咪唑二羧酸酯用市售的对应原料替换,步骤五中用所需的硼酸或者硼酸酯替换。
实施例64-75与实施例62类似,将步骤五中的胺用市售的所需的胺替换,步骤六中用所需的硼酸或者硼酸酯替换。
实施例76-88与实施例36类似,将步骤四中的胺用市售的所需的胺替换,步骤五中用所需的硼酸或者硼酸酯替换。
表1、实施例化合物数据表征
实施例89:细胞焦亡测试
以上化合物的体外活性在以下测定中证明:
使用THP-1人单核细胞(THP-1human monocytic cells,THP-1)对小分子化合物靶向抑制NLRP3炎症小体进行体外活性筛选。THP-1可被佛波酯(PMA)诱导分化为巨噬细胞,可再通过脂多糖(LPS)诱导巨噬细胞M1极化,释放出TNF-α、IL-6等细胞因子,建立典型的炎症模型。
1.实验材料:
RPMI Medium 1640培养基购自Gibco公司,青、链霉素购自Hyclone公司,脂多糖(LPS)、佛波酯(PMA)、尼日利亚菌素购自MedChemExpress(MCE)公司,噻唑蓝(MTT)购自北京索莱宝科技有限公司,十二烷基硫酸钠(SDS)购自Biofroxx公司。
2.THP-1细胞培养:
THP-1细胞采用1640培养基+10%FBS+1%青/链霉素培养基,置于37℃、5%CO2的培养箱中培养。
3.THP-1细胞焦亡测试:
收集处于对数生长期的THP-1细胞,制备1×106个/mL的细胞悬液,同时加入PMA并使其在细胞悬液里的终浓度为300ng/mL,然后以1×105个每孔接种于96孔板中,置于37℃、5%CO2的细胞培养箱中培养24小时,使细胞被诱导分化为巨噬细胞。
次日,加入LPS刺激细胞,诱导产生炎症模型,具体操作为:去掉孔板中原有的培养液,每孔加入100μL含有2μg/mL LPS的1640培养基,然后将96孔板置于37℃、5%CO2的细胞培养箱中培养3~4小时,建立炎症模型。每块96孔板中设置药物处理组、炎症模型组、正常细胞组(只含细胞和1640培养基)和空白对照组(不含细胞只含培养基)。LPS刺激结束后,用1640培养基稀释待测化合物到相应浓度(0.004-40μM)并加入到96孔板相应孔中,每孔50μL,每个样品浓度3个复孔;炎症模型组和正常细胞组加入50μL的1640培养基,然后将96孔板置于37℃、5%CO2的细胞培养箱中培养30min。培养结束后,药物处理组和炎症模型组分别加入50μL的含有40μM尼日利亚菌素的1640培养基,尼日利亚菌素可激活细胞的NLRP3炎症小体,诱导细胞焦亡;正常细胞组加入50μL的1640培养基。此时,在96孔板中200μL的体系里面,各药物的终浓度在0.001-10μM,尼日利亚菌素在终浓度为10μM。加完尼日利亚菌素后将96孔板置于37℃、5%CO2的细胞培养箱中培养3~4小时,培养结束后每孔加20μL的MTT溶液(5mg/mL),置于37℃、5%CO2的细胞培养箱孵育1.5h,然后每孔加50μL的20%SDS溶液(含0.1%盐酸),并将96孔板置于37℃、5%CO2的细胞培养箱中孵育过夜,第3天用酶标仪在562nm波长下检测吸光度。并根据以下公式计算药物对细胞的焦亡保护率:
细胞焦亡保护率=[(X-C0)/(C-C0)]×100%
其中,C、C0和X分别代表正常细胞组、空白对照组和药物处理组的平均吸光度值。最后,使用Graphpad Prism 5.0软件拟合细胞存活率曲线并计算出待测化合物抑制NLRP3炎症小体引起的细胞焦亡的EC50值。
表2:体外测定1中各实施例化合物的EC50值
对于EC50值,“+”表示EC50值大于1μM,“++”表示EC50值大于500nM小于等于1μM,“+++”表示EC50值大于100nM小于等于500nM;“++++”表示EC50值大于20nM小于等于100nM;“+++++”表示EC50值小于20nM。
Claims (10)
1.由以下化学式(I-0)表示的化合物或其药学上可以接受的盐:
其中:
n为0或1;
m选自1至5的整数;
p选自1或2;
X1、X2、X5分别独立地选自CH2、NH、CH、O、S或N;
X3、X4分别独立地选自CH2、CH或N;
R1选自氢、氘、C1-6烷基、C1-6烷氧基、C3-6环烷基、卤素、氧化膦基、羟基、氰基,所述C1-6烷基、C3-6环烷基、C1-6烷氧基、氧化膦基任选地被一个或多个卤素、C1-3烷基取代,其中,m个R1可以彼此相同或不同;
R3选自氢、氘、C1-6烷基、C1-6烷氧基、C3-6环烷基、卤素、氧化膦基、羧基、氰基,所述C1-6烷基、C1-6烷氧基、C3-6环烷基、氧化膦基任选地被一个或多个卤素、C1-3烷基取代,其中,p个R3可以彼此相同或不同;
A为单键或C1-3亚烷基链,任选地,所述C1-3亚烷基链中亚甲基上的一个或多个氢被C1-3烷基取代;
M为-NR10-、-O-或-S-
R4选自C1-6烷基、C3-9环烷基、C5-9芳基、3-9元杂环烷基、5-9元杂芳基、9-12元部分不饱和杂环双环,所述C1-6烷基、C3-9环烷基、C5-9芳基、3-9元杂环烷基、5-9元杂芳基、9-12元部分不饱和杂环双环任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、=O、-NR8R9取代;
R8、R9、R10分别独立地选自氢、C1-3烷基。
2.根据权利要求1的化合物或其药学上可以接受的盐,其中所述化合物具有式(I)所示的结构:
其中:
n为0或1;
m选自1至5的整数;
p选自1或2;
X1、X2、X5分别独立地选自CH2、NH、CH、O、S或N;
X3、X4分别独立地选自CH2、CH或N;
R1选自氢、氘、C1-6烷基、C1-6烷氧基、C3-6环烷基、卤素、氧化膦基、羟基、氰基,所述C1-6烷基、C3-6环烷基、C1-6烷氧基、氧化膦基任选地被一个或多个卤素、C1-3烷基取代,其中,m个R1可以彼此相同或不同;
R3选自氢、氘、C1-6烷基、C1-6烷氧基、C3-6环烷基、卤素、氧化膦基、羧基、氰基,所述C1-6烷基、C1-6烷氧基、C3-6环烷基、氧化膦基任选地被一个或多个卤素、C1-3烷基取代,其中,p个R3可以彼此相同或不同;
A为单键或C1-3亚烷基链,任选地,所述C1-3亚烷基链中亚甲基上的一个或多个氢被C1-3烷基取代;
R4选自C1-6烷基、C3-9环烷基、C5-9芳基、3-9元杂环烷基、5-9元杂芳基、9-12元部分不饱和杂环双环,所述C1-6烷基、C3-9环烷基、C5-9芳基、3-9元杂环烷基、5-9元杂芳基、9-12元部分不饱和杂环双环任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、=O、-NR8R9取代;
R8、R9分别独立地选自氢、C1-3烷基;
优选地,R4选自C1-6烷基、C3-9环烷基、C5-9芳基、3-9元杂环烷基、5-9元杂芳基、9-12元部分不饱和杂环双环,所述C1-6烷基、C3-9环烷基、C5-9芳基、3-9元杂环烷基、5-9元杂芳基、9-12元部分不饱和杂环双环任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、-NR8R9取代。
3.根据权利要求1或2的化合物或其药学上可以接受的盐,其中:
R1选自C1-3烷基、C1-3烷氧基、C3-6环烷基、氧化膦基、羟基、氰基、卤素,所述C1-3烷基、C1-3烷氧基、C3-6环烷基、氧化膦基任选地被一个至三个卤素、C1-3烷基取代;
优选地,R1选自C1-3烷基、C1-3烷氧基、羟基、氰基、卤素、氧化膦基,所述C1-3烷基、C1-3烷氧基、氧化膦基任选地被一个至三个氟、甲基取代;
优选地,R1选自三氟甲基、二氟甲基、甲基、氟、羟基、二甲基氧化膦基或三氟甲氧基;
优选地,R1选自三氟甲基、甲基、氟、羟基、二甲基氧化膦基或三氟甲氧基;
优选地,R1选自三氟甲基、甲基或羟基;
优选地,R3选自氢、C1-3烷基、C3-6环烷基、C1-3烷氧基、卤素、氧化膦基,所述C1-3烷基、C1-3烷氧基、C3-6环烷基、氧化膦基任选地被一个至三个卤素、C1-3烷基取代;
优选地,R3选自C1-3烷基、C1-3烷氧基、C3-6环烷基、氧化膦基,所述C1-3烷基、C1-3烷氧基、C3-6环烷基、氧化膦基任选地被一个至三个氟、甲基取代;
优选地,R3选自氢、甲基、甲氧基、环丙烷基、乙基、氟、三氟甲基或二甲基氧化膦基;
优选地,R3选自氢、甲基、甲氧基;
优选地,A为单键或C1-3亚烷基链,任选地,所述C1-3亚烷基链中亚甲基上的一个或多个氢被甲基取代;
优选地,A为单键、-CH2-、-(CH3)CH-、-CH2CH2-;
优选地,A为单键;
优选地,R4选自C1-6烷基、C5-8环烷基、苯基、含有1-2个分别独立地选自N、O、S原子的5-7元杂环烷基、含有1-2个分别独立地选自N、O、S原子的5-7元杂芳基、含有1-2个分别独立地选自N、O、S原子的9-12元部分不饱和杂环双环,所述C1-6烷基、C5-8环烷基、苯基、含有1-2个分别独立地选自N、O、S原子的5-7元杂环烷基、含有1-2个分别独立地选自N、O、S原子的5-7元杂芳基、含有1-2个分别独立地选自N、O、S原子的9-12元部分不饱和杂环双环任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、卤代C1-3烷基、=O、-NR8R9取代;
优选地,R4选自C1-6烷基、C5-8环烷基、苯基、含有1-2个分别独立地选自N、O、S原子的5-7元杂环烷基、含有1-2个分别独立地选自N、O、S原子的5-7元杂芳基、含有1-2个分别独立地选自N、O、S原子的9-12元部分不饱和杂环双环,所述C1-6烷基、C5-8环烷基、苯基、含有1-2个分别独立地选自N、O、S原子的5-7元杂环烷基、含有1-2个分别独立地选自N、O、S原子的5-7元杂芳基、含有1-2个分别独立地选自N、O、S原子的9-12元部分不饱和杂环双环任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、-NR8R9取代;
优选地,R4选自C1-6烷基、C5-8环烷基、苯基、含有1-2个分别独立地选自N、O原子的5-7元杂环烷基、含有1个N原子的5-7元杂芳基、含有1个N原子的9-12元部分不饱和杂环双环,所述C1-6烷基、C5-8环烷基、苯基、含有1-2个分别独立地选自N、O原子的5-7元杂环烷基、含有1个N原子的5-7元杂芳基、含有1个N原子的9-12元部分不饱和杂环双环任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、卤代C1-3烷基、=O、-NR8R9取代;
优选地,R4选自C1-6烷基、C5-8环烷基、苯基、含有1-2个分别独立地选自N、O原子的5-7元杂环烷基、含有1个N原子的5-7元杂芳基、含有1个N原子的9-12元部分不饱和杂环双环,所述C1-6烷基、C5-8环烷基、苯基、含有1-2个分别独立地选自N、O原子的5-7元杂环烷基、含有1个N原子的5-7元杂芳基、含有1个N原子的9-12元部分不饱和杂环双环任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、-NR8R9取代;
优选地,R4选自正丁基、环己基、苯基、哌啶基、吡啶基、吡咯基、吡咯烷基、吗啉基、四氢吡喃基、所述环己基、苯基、哌啶基、吡啶基、吡咯基、吡咯烷基任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、卤代C1-3烷基、=O、-NR8R9取代;
优选地,R4选自正丁基、环己基、苯基、哌啶基、吡啶基、吡咯基、吡咯烷基、吗啉基、所述环己基、苯基、哌啶基、吡啶基、吡咯基、吡咯烷基任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、-NR8R9取代;
优选地,R4选自正丁基、环己基、苯基、哌啶基、吡啶基、吡咯烷基、吗啉基、四氢吡喃基、所述环己基、苯基、哌啶基、吡啶基、吡咯烷基任选地被一个至二个氟、羟基、甲基、乙基、乙酰基、卤代C1-3烷基、=O、-N(CH3)2取代;
优选地,R8、R9为甲基。
4.根据权利要求1-3任一项的化合物或其药学上可以接受的盐,其中,所述化合物具有式(II)所示的结构:
其中:
n、X1、X2、X3、X4、X5、R3、R4、A的定义如权利要求1、2或3所定义;
R11选自氢、氘、C1-6烷基、C1-6烷氧基、C3-6环烷基、卤素、氧化膦基,所述C1-6烷基、C3-6环烷基、C1-6烷氧基、氧化膦基任选地被一个或多个卤素、C1-3烷基取代;
优选地,R11选自氢、C1-3烷基、C1-3烷氧基、氧化膦基、卤素、C3-6环烷基,所述C1-3烷基、C1-3烷氧基、C3-6环烷基、氧化膦基任选地被一个至三个卤素、C1-3烷基取代;
优选地,R11选自氢、C1-3烷基、C1-3烷氧基、卤素、氧化膦基,所述C1-3烷基、C1-3烷氧基、氧化膦基任选地被一个至三个氟、甲基取代;
优选地,R11选自氢、三氟甲基、甲基、氟、二甲基氧化膦基或三氟甲氧基;
优选地,R11选自三氟甲基、甲基、三氟甲氧基、氟;
R2选自氢、氘、C1-6烷基、羟基、卤素、氰基、二氟甲基;
优选地,R2选自氢、氘、C1-6烷基、羟基、卤素、氰基;
优选地,R2选自羟基、二氟甲基;
优选地,R2选自羟基;
R5、R6、R7分别独立地选自氢、卤素、C1-3烷基;
优选地,R5、R6、R7分别独立地选自氢、氟、甲基。
5.根据权利要求1-4任一项的化合物或其药学上可以接受的盐,其中,所述化合物具有式(III)所示的结构:
其中:
n、X1、X2、R11、R3、R4、A如权利要求1、2或3所定义;
优选地,所述化合物具有式(IV)所示的结构:
其中:
X1、X2、R11、R3、R4、A如权利要求1、2或3所定义;
优选地,所述化合物具有式(IVa)、(IVb)、(IVc)、(IVd)、或(IVe)所示的结构:
其中:
R1、R3、R4、A如权利要求1、2或3所定义;
或者,根据权利要求1-4任一项的化合物或其药学上可以接受的盐,其中,所述化合物具有式(V)或式(VI)所示的结构:
其中:
R3、R4、A如权利要求1、2或3所定义。
6.根据权利要求1的化合物或其药学上可以接受的盐,其中,所述化合物具有式(I-1)所示的结构:
其中:
n为0或1;
m选自1至5的整数;
p选自1或2;
X1、X2、X5、X6分别独立地选自CH2、NH、CH、O、S或N;
X3、X4分别独立地选自CH2、CH或N;
R1选自氢、氘、C1-6烷基、C1-6烷氧基、C3-6环烷基、卤素、氧化膦基、羟基、氰基,所述C1-6烷基、C3-6环烷基、C1-6烷氧基、氧化膦基任选地被一个或多个卤素、C1-3烷基取代,其中,m个R1可以彼此相同或不同;
R3选自氢、氘、C1-6烷基、C1-6烷氧基、C3-6环烷基、卤素、氧化膦基、羧基、氰基,所述C1-6烷基、C1-6烷氧基、C3-6环烷基、氧化膦基任选地被一个或多个卤素、C1-3烷基取代,其中,p个R3可以彼此相同或不同;
A为单键或C1-3亚烷基链,任选地,所述C1-3亚烷基链中亚甲基上的一个或多个氢被C1-3烷基取代;
R4选自C1-6烷基、C3-9环烷基、C5-9芳基、3-9元杂环烷基、5-9元杂芳基、9-12元部分不饱和杂环双环,所述C1-6烷基、C3-9环烷基、C5-9芳基、3-9元杂环烷基、5-9元杂芳基、9-12元部分不饱和杂环双环任选地被一个或多个卤素、羟基、C1-3烷基、C1-6酰基、=O、-NR8R9取代;
R8、R9分别独立地选自氢、C1-3烷基;
优选地,所述X6选自S。
8.根据权利要求1-6任一项化合物或其药学上可接受的盐的制备方法,所述方法包括以下步骤:
步骤一:将化合物A0溶于POCl3中,加热,反应过夜,反应完全后,将反应液直接浓缩,除掉POCl3后,将油状粗品慢慢滴加入冰水中,乙酸乙酯萃取,经过柱层析分离得到目标化合物A1;
步骤二:将化合物A1,相应的胺,Na2CO3溶于干燥DMF中,此混合体系置于封管中加热,反应过夜,原料转化完全后,将反应液加入到水中,乙酸乙酯萃取,经过柱层析分离得到目标化合物A2;
步骤三:将化合物A2,硼酸,碳酸钠和Pd(dppf)Cl2加入到二氧六环和水的混合溶剂中,氮气置换3次,加热,反应3小时,将反应液加入到水中,乙酸乙酯萃取,经过柱层析分离得到目标化合物I-0。
9.一种药物组合物,其特征在于,所述组合物包含根据权利要求1-7任一项的化合物或其药学上可接受的盐和药学上可接受的辅料。
10.权利要求1-7任一项的化合物或其药学上可接受的盐、权利要求8的药物组合物在制备治疗NLRP3介导的病症的药物的应用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021111660908 | 2021-09-30 | ||
CN202111166090 | 2021-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115417856A true CN115417856A (zh) | 2022-12-02 |
Family
ID=84206979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211210361.XA Pending CN115417856A (zh) | 2021-09-30 | 2022-09-30 | 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 |
Country Status (4)
Country | Link |
---|---|
CN (1) | CN115417856A (zh) |
AU (1) | AU2022355409A1 (zh) |
CA (1) | CA3233482A1 (zh) |
WO (1) | WO2023051761A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
CN116789674A (zh) * | 2022-08-24 | 2023-09-22 | 杭州高光制药有限公司 | Nlrp3炎性小体抑制剂 |
WO2023186020A1 (en) * | 2022-03-31 | 2023-10-05 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Nlrp3 inflammasome inhibitors |
WO2024094185A1 (zh) * | 2022-11-04 | 2024-05-10 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
CN116789674B (zh) * | 2022-08-24 | 2024-05-24 | 杭州高光制药有限公司 | Nlrp3炎性小体抑制剂 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024006559A1 (en) * | 2022-07-01 | 2024-01-04 | Neumora Therapeutics, Inc. | Modulators of nlrp3 inflammasome and related products and methods |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3753988A (en) * | 1969-05-03 | 1973-08-21 | Aspro Nicholas Ltd | Substituted phthalazines |
WO2006004589A2 (en) * | 2004-05-08 | 2006-01-12 | Neurogen Corporation | 3-aryl-5,6-disubstituted pyridazines |
WO2007066615A1 (ja) * | 2005-12-05 | 2007-06-14 | Mitsubishi Tanabe Pharma Corporation | 核内オーファン受容体の新規活性化剤及びその用途 |
US20090124624A1 (en) * | 2005-10-12 | 2009-05-14 | Sanofi-Aventis | Substituted 1-aminophthalazine derivatives, preparation thereof and therapeutic application thereof |
WO2018080216A1 (en) * | 2016-10-28 | 2018-05-03 | Daewoong Pharmaceutical Co., Ltd. | Phenyl phthalazine derivative, method for the preparation thereof, and pharmaceutical composition comprising the same |
WO2018221433A1 (ja) * | 2017-05-29 | 2018-12-06 | 第一三共株式会社 | ヘテロアリールアミン誘導体 |
US11319319B1 (en) * | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
CN115433163A (zh) * | 2021-06-05 | 2022-12-06 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
CN116390914A (zh) * | 2020-12-25 | 2023-07-04 | 上海拓界生物医药科技有限公司 | 一类含哒嗪的化合物及其医药用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW279162B (zh) * | 1991-09-26 | 1996-06-21 | Mitsubishi Chem Corp | |
AR119731A1 (es) * | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
-
2022
- 2022-09-30 AU AU2022355409A patent/AU2022355409A1/en active Pending
- 2022-09-30 CN CN202211210361.XA patent/CN115417856A/zh active Pending
- 2022-09-30 CA CA3233482A patent/CA3233482A1/en active Pending
- 2022-09-30 WO PCT/CN2022/123126 patent/WO2023051761A1/zh active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3753988A (en) * | 1969-05-03 | 1973-08-21 | Aspro Nicholas Ltd | Substituted phthalazines |
WO2006004589A2 (en) * | 2004-05-08 | 2006-01-12 | Neurogen Corporation | 3-aryl-5,6-disubstituted pyridazines |
US20090124624A1 (en) * | 2005-10-12 | 2009-05-14 | Sanofi-Aventis | Substituted 1-aminophthalazine derivatives, preparation thereof and therapeutic application thereof |
WO2007066615A1 (ja) * | 2005-12-05 | 2007-06-14 | Mitsubishi Tanabe Pharma Corporation | 核内オーファン受容体の新規活性化剤及びその用途 |
WO2018080216A1 (en) * | 2016-10-28 | 2018-05-03 | Daewoong Pharmaceutical Co., Ltd. | Phenyl phthalazine derivative, method for the preparation thereof, and pharmaceutical composition comprising the same |
WO2018221433A1 (ja) * | 2017-05-29 | 2018-12-06 | 第一三共株式会社 | ヘテロアリールアミン誘導体 |
CN116390914A (zh) * | 2020-12-25 | 2023-07-04 | 上海拓界生物医药科技有限公司 | 一类含哒嗪的化合物及其医药用途 |
US11319319B1 (en) * | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
CN115433163A (zh) * | 2021-06-05 | 2022-12-06 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
Non-Patent Citations (2)
Title |
---|
E.A.KASSAB: "Synthesis and behaviour of 4-(4’-chloro-3’-methyl phenyl)1-(2H)-phthalazinone towards certain electrophiles and nucleophiles", 《EGYPT.J.CHEM.》, 31 December 2005 (2005-12-31), pages 183 - 199 * |
MAUD BOLLENBACH 等: "Design and synthesis of 3-aminophthalazine derivatives and structural analogues as PDE5 inhibitors: anti-allodynic effect against neuropathic pain in a mouse model", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, 22 May 2019 (2019-05-22), pages 269 - 290 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
WO2023186020A1 (en) * | 2022-03-31 | 2023-10-05 | Hangzhou Highlightll Pharmaceutical Co., Ltd | Nlrp3 inflammasome inhibitors |
CN116789674A (zh) * | 2022-08-24 | 2023-09-22 | 杭州高光制药有限公司 | Nlrp3炎性小体抑制剂 |
CN116789674B (zh) * | 2022-08-24 | 2024-05-24 | 杭州高光制药有限公司 | Nlrp3炎性小体抑制剂 |
WO2024094185A1 (zh) * | 2022-11-04 | 2024-05-10 | 药捷安康(南京)科技股份有限公司 | Nlrp3炎症小体抑制剂及其应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2023051761A1 (zh) | 2023-04-06 |
CA3233482A1 (en) | 2023-04-06 |
AU2022355409A1 (en) | 2024-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115417856A (zh) | 一类取代杂芳酞嗪衍生物的药学用途及其制备方法 | |
CN112368283B (zh) | 含二并环类衍生物抑制剂、其制备方法和应用 | |
JP3544675B2 (ja) | 血管形成阻害活性を有するフタラジン | |
JP6035423B2 (ja) | 新規な縮合ピリミジン化合物又はその塩 | |
US20050143371A1 (en) | Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors | |
KR20180083421A (ko) | 단백질 키나아제 억제제 및 이의 제조방법과 의학적 용도 | |
CN112724145A (zh) | 用于抑制shp2活性的吡嗪衍生物 | |
US20060281763A1 (en) | Carboxamide inhibitors of TGFbeta | |
EP2632260A1 (en) | Leucine-rich repeat kinase enzyme activity | |
CN110167941B (zh) | 取代的稠合杂芳基化合物作为激酶抑制剂及其应用 | |
CN101951776A (zh) | 四氢-1h-吡咯稠合吡啶酮 | |
TWI523856B (zh) | BCR-ABL kinase inhibitor and its application | |
TWI623538B (zh) | 三環化合物 | |
WO2022012409A1 (zh) | 一种rock抑制剂及其制备方法和用途 | |
CN115279749A (zh) | Shp2抑制剂及其组合物和应用 | |
CN111560012A (zh) | 一种作为irak抑制剂的化合物 | |
JP2023538091A (ja) | Btk阻害剤としての複素環式化合物 | |
TW202400601A (zh) | 作為parp抑製劑的取代的三環類化合物及其用途 | |
CN114835687A (zh) | AhR抑制剂 | |
JP6607962B2 (ja) | β−グルクロニダーゼの阻害のためのピラゾロ[4,3−c]キノリン誘導体 | |
WO2020156319A1 (zh) | N-甲酰胺衍生物、其制备方法及其在医药上的用途 | |
CN113166141A (zh) | 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 | |
WO2021121390A1 (zh) | 杂环化合物及其药物组合物、制备方法、中间体和应用 | |
WO2020207419A1 (zh) | 哌嗪酰胺衍生物,其制备方法及其在医药上的用途 | |
CN111909133A (zh) | 作为布鲁诺酪氨酸激酶抑制剂的取代的1-氨基-1h-咪唑-5-甲酰胺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |